Alzheimer's Disease

1. Clinical Overview

Summary

Alzheimer's Disease (AD) is the most common cause of dementia, accounting for 60-80% of all cases worldwide. It is a progressive neurodegenerative disorder characterised by insidious onset and gradual decline in memory (particularly recent episodic memory), followed by deterioration in other cognitive domains including language, visuospatial function, and executive function. [1,2]

Pathologically, AD is defined by extracellular amyloid-beta (Aβ) plaques composed of aggregated Aβ peptides (particularly Aβ42), and intracellular neurofibrillary tangles (NFTs) consisting of hyperphosphorylated tau protein. These proteinopathies lead to synaptic dysfunction, neuronal loss, and progressive brain atrophy, particularly affecting the hippocampus and medial temporal lobes. [3,4]

The typical patient is over 65 years old with gradual memory decline noted by family members, often presenting with repetitive questioning, misplacing items, and difficulty learning new information. Diagnosis is clinical, supported by cognitive testing (MMSE, ACE-III, MoCA), neuroimaging (MRI showing hippocampal atrophy), and exclusion of reversible causes. [5,6]

Management involves acetylcholinesterase inhibitors (AChEIs) - Donepezil, Rivastigmine, and Galantamine - for mild-to-moderate disease, and Memantine (NMDA receptor antagonist) for moderate-to-severe disease. These medications provide modest symptomatic benefit but do not halt disease progression. Non-pharmacological interventions including cognitive stimulation therapy, physical activity, and carer support are essential components of holistic care. [7,8]

The disease is progressive and ultimately fatal, with median survival of 8-10 years from symptom onset. Death typically results from complications including aspiration pneumonia, infections, or falls. Novel anti-amyloid monoclonal antibodies (lecanemab, donanemab) show modest disease-modifying effects in early AD but remain under evaluation for widespread clinical use. [9,10]

Clinical Pearls

"Memory First": Alzheimer's typically starts with episodic memory loss (especially recent memory). If personality/behaviour changes or language deficits come first, consider Frontotemporal Dementia or Primary Progressive Aphasia.

"Hippocampal Atrophy": MRI shows bilateral medial temporal lobe atrophy (hippocampus and entorhinal cortex). This correlates with severity of memory impairment and is a key diagnostic feature.

"Aβ Plaques and Tau Tangles": The pathological hallmarks. Amyloid plaques (extracellular) appear early; Tau tangles (intracellular) correlate better with cognitive decline and follow predictable spreading pattern (Braak staging).

"Cholinergic Hypothesis": Loss of cholinergic neurons in the Nucleus Basalis of Meynert → Acetylcholine deficiency → Memory and cognitive impairment. This forms the rationale for AChEI therapy.

"APOE ε4 - Risk NOT Destiny": APOE ε4 allele is the strongest genetic risk factor for late-onset AD. Heterozygotes (one copy) have ~3x risk; Homozygotes (two copies) have ~12x risk. However, NOT deterministic - many carriers never develop AD.

2. Epidemiology

Global Burden

Factor	Statistics
Global Prevalence	~55 million people worldwide (2020). Projected to reach 139 million by 2050. [1,11]
New Cases	One new case every 3 seconds globally. ~10 million new cases annually. [11]
Economic Impact	Global dementia costs exceed $1.3 trillion annually (2019). Expected to reach $2.8 trillion by 2030. [11]

Demographics

Factor	Notes
Prevalence by Age	~7-8% of adults over 65. ~15% of over 75s. ~40% of over 85s. [1,2]
Age as Risk Factor	Risk doubles approximately every 5 years after age 65. [2]
Sex Distribution	Women > Men (1.6:1 ratio). Partly explained by longevity, but sex-specific risk factors also contribute. [12]
Ethnic Differences	Higher prevalence in African-Americans and Hispanics compared to Non-Hispanic Whites in USA. [12]
Geographic Variation	Highest age-standardised prevalence in Western Europe and North America. Lower in Sub-Saharan Africa (may reflect under-diagnosis). [11]

Age-Specific Prevalence

Age Group	Prevalence
60-64 years	~1%
65-69 years	~2%
70-74 years	~3-4%
75-79 years	~8%
80-84 years	~16%
85+ years	~30-40%

Classification by Age of Onset

Type	Age of Onset	Proportion	Key Features
Late-Onset AD (LOAD)	≥65 years	95%	Sporadic. APOE ε4 main genetic risk. Complex multifactorial aetiology.
Early-Onset AD (EOAD)	less than 65 years	5%	Often familial. May have autosomal dominant mutations (APP, PSEN1, PSEN2). More aggressive course.

Risk Factors

Non-Modifiable Risk Factors

Risk Factor	Relative Risk	Notes
Age	Strongest predictor	Risk doubles every ~5 years after age 65. [2]
Family History	2-3x	First-degree relative with AD. Higher if multiple relatives or young-onset cases. [13]
APOE ε4 Allele	3-12x	Heterozygotes (ε3/ε4): ~3x risk. Homozygotes (ε4/ε4): ~12x risk. [14]
Female Sex	1.6x	Independent of longevity. Hormonal and biological factors. [12]
Down Syndrome (Trisomy 21)	Near universal by age 40	APP gene located on Chromosome 21 → Triple gene dosage → Early Aβ accumulation. [15]

Modifiable Risk Factors (Vascular and Lifestyle)

Risk Factor	Relative Risk	Notes
Hypertension	1.6-2.0x	Midlife hypertension particularly important. [16]
Type 2 Diabetes	1.5-2.0x	Insulin resistance, hyperglycaemia, vascular mechanisms. [16]
Obesity (Midlife)	1.6x	BMI > 30 in midlife. Late-life obesity may be protective (reverse causation). [16]
Physical Inactivity	1.4x	Sedentary lifestyle. [16]
Smoking	1.6x	Vascular damage. Risk decreases after cessation. [16]
Hypercholesterolaemia	1.3-1.5x	Midlife high cholesterol. Statin use shows conflicting evidence. [16]
Depression	1.9x	May be prodrome OR independent risk factor. Bidirectional relationship. [16]
Social Isolation	1.6x	Lack of social engagement. [16]
Low Educational Attainment	1.6x	Less "Cognitive Reserve". Education less than 12 years. [16]
Traumatic Brain Injury	1.5-2.0x	History of moderate-severe TBI. Repeated mild TBI (sports). [17]
Hearing Loss	1.9x	Untreated hearing impairment in midlife. [16]
Excessive Alcohol	1.2x	> 14 units/week. Both excess AND abstinence associated with risk (U-shaped). [16]

Protective Factors

Factor	Effect	Mechanism
Higher Education	Protective	Cognitive reserve. Neural redundancy. [18]
Physical Activity	Protective	Aerobic exercise improves cerebral blood flow, neuroplasticity, reduces vascular risk. [16,18]
Mediterranean Diet	Protective	Antioxidants, omega-3 fatty acids, anti-inflammatory. [18]
Cognitive Engagement	Protective	Lifelong learning, mentally stimulating activities. [18]
Social Engagement	Protective	Social networks, volunteering, group activities. [16,18]
Good Sleep	Protective	Sleep disruption impairs Aβ clearance. [18]

3. Pathophysiology

Macroscopic Pathology

Feature	Description
Brain Weight	Reduced by 20-30% in advanced AD (normal ~1400g → ~1000g).
Cortical Atrophy	Generalised cortical thinning, widened sulci, enlarged ventricles.
Hippocampal Atrophy	Bilateral medial temporal lobe atrophy - earliest and most characteristic finding. Involves hippocampus, entorhinal cortex, and parahippocampal gyrus.
Regional Distribution	Early: Medial temporal lobes. Late: Frontal, parietal, temporal association cortices. Sparing: Primary motor, sensory cortex, occipital cortex (until very late).

Microscopic Pathology: Hallmark Features

1. Amyloid-Beta (Aβ) Plaques

Aspect	Details
Composition	Extracellular deposits of Amyloid-beta peptide (Aβ), predominantly Aβ40 and Aβ42. Aβ42 is more hydrophobic and prone to aggregation. [3,4]
Formation	APP (Amyloid Precursor Protein) is cleaved by β-secretase (BACE1) and γ-secretase → Generates Aβ peptides. Normally cleared by proteolytic degradation and glial phagocytosis. In AD, imbalance between production and clearance. [3]
Types of Plaques	Diffuse plaques: Early, non-neuritic, less pathogenic. Neuritic (senile) plaques: Core of Aβ surrounded by dystrophic neurites, activated microglia, reactive astrocytes. These are pathogenic. [4]
Toxic Species	Soluble Aβ oligomers are most toxic - impair synaptic function, disrupt ion homeostasis, induce oxidative stress. [3]
Distribution	Begin in neocortex, spread to hippocampus and other regions.

2. Neurofibrillary Tangles (NFTs)

Aspect	Details
Composition	Intracellular aggregates of hyperphosphorylated tau protein. Paired helical filaments (PHFs) visible on electron microscopy. [3,4]
Normal Tau Function	Tau is a microtubule-associated protein (MAP). Stabilises microtubules in axons → Essential for axonal transport and neuronal integrity. [4]
Pathological Tau	In AD, tau becomes hyperphosphorylated at multiple serine/threonine residues → Dissociates from microtubules → Self-aggregates into PHFs → Forms NFTs. [4]
Toxic Effects	Microtubule destabilisation → Impaired axonal transport → Synaptic dysfunction → Neuronal death. Tau oligomers and aggregates are directly neurotoxic. [4]
Spread Pattern	NFTs spread in predictable sequence (Braak Staging) correlating with clinical progression. Better correlation with cognitive decline than Aβ plaques. [19]
Post-Mortem Persistence	NFTs persist after neuronal death as "ghost tangles".

3. Braak Staging (Neuropathological Progression of Tau)

Braak Stage	Region	Clinical Correlation
Stage I-II	Transentorhinal cortex	Clinically silent or very mild memory impairment.
Stage III-IV	Hippocampus and limbic regions	Mild Cognitive Impairment or Mild AD. Memory deficits prominent.
Stage V-VI	Neocortical association areas	Moderate-Severe AD. Global cognitive impairment.

4. Neuronal Loss and Synaptic Dysfunction

Feature	Details
Neuronal Death	Progressive loss of neurons, especially in hippocampus (CA1 subfield), entorhinal cortex, and association cortices. Up to 30-40% neuronal loss in affected regions. [4]
Synaptic Loss	Synaptic dysfunction and loss precede neuronal death. Strong correlation with cognitive decline. May be earliest pathological change. [4]
White Matter Changes	Myelin loss, white matter degeneration secondary to axonal damage.

5. Cholinergic Deficit

Feature	Details
Nucleus Basalis of Meynert	Located in basal forebrain. Provides cholinergic innervation to hippocampus and cortex. Severe neuronal loss in AD (~70-90%). [20]
Acetylcholine Deficiency	Profound reduction in acetylcholine and choline acetyltransferase (ChAT) activity in cortex and hippocampus. [20]
Functional Consequence	Cholinergic system critical for memory encoding, attention, executive function. Deficit explains many cognitive symptoms.
Therapeutic Implication	Rationale for Acetylcholinesterase Inhibitor (AChEI) therapy to boost synaptic acetylcholine. [7,20]

6. Neuroinflammation

Feature	Details
Microglial Activation	Chronic activation of microglia around plaques and tangles. Initially phagocytic (beneficial), but becomes pro-inflammatory (harmful). [3]
Astrocytic Gliosis	Reactive astrocytes surround plaques. Produce inflammatory cytokines (IL-1β, IL-6, TNF-α). [3]
Complement Activation	Classical complement pathway activated. Contributes to synaptic pruning and neuronal damage. [3]
Role in Pathogenesis	Neuroinflammation amplifies Aβ and tau toxicity. Both protective (clearance) and pathogenic (chronic inflammation) roles. [3]

Molecular Pathophysiology: The Amyloid Cascade Hypothesis

Central Hypothesis: Aβ accumulation is the initiating event triggering downstream pathology. [3]

AMYLOID CASCADE HYPOTHESIS

1. AMYLOID PRECURSOR PROTEIN (APP) PROCESSING
   APP (Chromosome 21) → Cleavage by β-secretase (BACE1) + γ-secretase
                       → Generates Aβ40 and Aβ42 peptides
                       
   Normal pathway: α-secretase cleaves APP → Non-amyloidogenic
   Pathological pathway: β/γ-secretase → Amyloidogenic Aβ
                       
                       ↓

2. Aβ ACCUMULATION
   Imbalance: Production > Clearance
   Aβ42 aggregates into oligomers → Protofibrils → Fibrils → Plaques
   **Soluble oligomers** = Most toxic species
                       
                       ↓

3. SYNAPTIC DYSFUNCTION
   Aβ oligomers:
   - Bind to synaptic receptors (NMDA, insulin receptor)
   - Impair long-term potentiation (LTP)
   - Disrupt calcium homeostasis
   - Induce oxidative stress
   - Cause synaptic loss
                       
                       ↓

4. TAU HYPERPHOSPHORYLATION
   Aβ triggers kinase activation (GSK-3β, CDK5) + Phosphatase inhibition
   → Tau hyperphosphorylated at 30+ sites
   → Tau detaches from microtubules
   → Self-aggregates into PHFs → Neurofibrillary Tangles
                       
                       ↓

5. MICROTUBULE DISRUPTION + AXONAL TRANSPORT FAILURE
   Loss of tau function → Microtubule instability
   → Impaired axonal transport
   → Synaptic dysfunction
                       
                       ↓

6. NEUROINFLAMMATION
   Microglial activation, astrocytic gliosis
   Chronic inflammatory cytokine release
   Complement activation
   Failed Aβ clearance
                       
                       ↓

7. NEURONAL DEATH
   Apoptosis, necrosis, autophagy failure
   Progressive atrophy
   Clinical dementia

Critiques of Amyloid Hypothesis:

Many elderly have significant Aβ burden without dementia.
Anti-amyloid therapies show modest clinical benefit despite plaque clearance.
Tau pathology correlates better with cognitive decline.
Alternative/complementary hypotheses: Tau-centric, mitochondrial dysfunction, vascular, inflammation-driven.

Genetics

Familial Alzheimer's Disease (Autosomal Dominant - Early Onset)

Gene	Chromosome	Protein	Prevalence	Notes
APP	21	Amyloid Precursor Protein	less than 5% of EOAD	Mutations increase Aβ production or Aβ42:Aβ40 ratio. Explains AD in Down Syndrome (APP gene triplication). [15]
PSEN1	14	Presenilin 1	~50% of EOAD	Most common cause of familial EOAD. Presenilin is part of γ-secretase complex. Mutations increase Aβ42 production. [15]
PSEN2	1	Presenilin 2	~5% of EOAD	Rare. Similar mechanism to PSEN1. Later onset than PSEN1 mutations. [15]

Clinical Features of Familial AD:

Autosomal dominant inheritance (50% risk to offspring).
Early onset (typically 30s-50s, some as young as 20s).
Aggressive course, faster progression.
100% penetrance for most mutations.
Genetic counselling and predictive testing available.

Sporadic Alzheimer's Disease (Late Onset)

Gene	Allele	Effect	Notes
APOE (Chromosome 19)	ε4	Risk allele	ε2/ε3/ε4 variants exist. ε3/ε3 (most common): Baseline risk. ε3/ε4 (heterozygous): ~3x risk. Earlier onset by ~5-10 years. ε4/ε4 (homozygous): ~12x risk. Onset may be in 60s. NOT deterministic - Many ε4 carriers never develop AD. [14]
APOE	ε2	Protective	ε2 allele associated with reduced risk and later onset. [14]

Mechanism of APOE ε4:

APOE protein involved in lipid transport and Aβ clearance.
ε4 variant less efficient at Aβ clearance → Increased plaque burden.
ε4 also affects tau pathology, neuroinflammation, and vascular integrity.

Other Genetic Risk Loci (Genome-Wide Association Studies):

Over 75 genetic loci identified with small effect sizes.
Implicated pathways: Immune response (TREM2, CD33, CR1), lipid metabolism (CLU, ABCA7), endocytosis (PICALM, BIN1).
Polygenic risk scores being developed for prediction.

4. Differential Diagnosis

Condition	Onset	Memory	Other Cognitive Domains	Motor Features	Imaging	Key Distinguishing Features
Alzheimer's Disease	Gradual	Early episodic memory loss (prominent)	Later: Language, visuospatial, executive.	None until late.	Hippocampal + medial temporal atrophy.	Memory-first presentation. Elderly. Hippocampal atrophy.
Vascular Dementia	Stepwise or gradual	Variable (depends on lesion location)	Executive dysfunction common.	Focal signs, gait disturbance, pseudobulbar palsy.	Multiple infarcts, strategic strokes, white matter disease.	Stepwise decline. Vascular risk factors. Strokes on imaging.
Frontotemporal Dementia (FTD)	Gradual	Relatively preserved early	Behavioural variant (bvFTD): Personality, disinhibition, apathy. Language variants: PPA.	Late parkinsonism or MND.	Frontal and/or anterior temporal atrophy.	Behaviour/personality FIRST. Younger onset (50-60s). Frontotemporal atrophy.
Lewy Body Dementia (DLB)	Gradual, fluctuating	Impaired but fluctuates	Visuospatial, executive, attention.	Parkinsonism (rigidity, bradykinesia). RBD.	Relative preservation of medial temporal lobe.	Visual hallucinations (recurrent, detailed). Parkinsonism. Fluctuating cognition. REM sleep behaviour disorder.
Parkinson's Disease Dementia (PDD)	Gradual	Impaired	Executive, visuospatial.	Parkinsonism FIRST (> 1 year before dementia).	Dopaminergic deficit on DaTscan.	Parkinson's motor features predate dementia by > 1 year.
Mild Cognitive Impairment (MCI)	Gradual	Objective impairment on testing	May be single or multiple domains.	None.	Variable (may show early atrophy).	Functional independence preserved. May progress to AD (~10-15%/year).
Depression (Pseudodementia)	Acute/subacute	Subjective >> Objective impairment	Poor effort, "don't know" answers.	Psychomotor retardation.	Normal or minimal changes.	Low mood, anhedonia. Poor effort on testing. Reversible with antidepressants.
Delirium	Acute (hours-days)	Acutely impaired	Inattention, disorientation.	Variable (agitated/hyperactive vs hypoactive).	Underlying cause.	Acute onset. Fluctuating. Reversible cause (infection, drugs, metabolic).
Normal Pressure Hydrocephalus (NPH)	Subacute/gradual	Impaired	Executive, processing speed.	Triad: Gait apraxia, urinary incontinence, dementia.	Ventriculomegaly out of proportion to atrophy.	Gait disturbance + Urinary incontinence + Dementia. Potentially reversible with VP shunt.
Creutzfeldt-Jakob Disease (CJD)	Rapid (weeks-months)	Rapidly progressive	Global rapid decline.	Myoclonus, ataxia, pyramidal/extrapyramidal.	DWI hyperintensity (cortical ribboning, basal ganglia). EEG: PSWCs.	RAPID dementia (weeks-months, not years). Myoclonus. Prion disease.
Chronic Subdural Haematoma	Subacute	Variable	Confusion, fluctuation.	Headache, focal signs.	Subdural collection on CT/MRI.	History of head trauma (often minor/remote). Reversible with drainage.
B12 Deficiency	Gradual	Impaired	Variable.	Peripheral neuropathy, subacute combined degeneration of cord.	MRI: Dorsal column T2 signal.	Low B12. Macrocytic anaemia. Reversible (if treated early).
Hypothyroidism	Gradual	Impaired	Psychomotor slowing.	Bradycardia, weight gain, fatigue.	Normal.	Low T4, High TSH. Reversible with levothyroxine.

Key Differentiators:

Alzheimer's: Memory FIRST, gradual, elderly, hippocampal atrophy.
FTD: Behaviour/language FIRST, younger (50-60s), frontal/temporal atrophy.
DLB: Visual hallucinations + Parkinsonism + Fluctuating cognition.
Vascular: Stepwise, vascular risks, strokes on imaging.
NPH: Triad (gait + incontinence + dementia), large ventricles, reversible.
CJD: RAPID (weeks-months), myoclonus, EEG changes.

5. Clinical Presentation

Natural History and Stages

Preclinical AD (Asymptomatic)

Feature	Details
Duration	May last 10-20 years before symptoms.
Pathology Present	Aβ accumulation on PET, CSF biomarker changes, subtle neuronal dysfunction.
Clinical Status	No symptoms. Cognitively normal. Functionally independent.
Detection	Research setting: Amyloid PET, CSF biomarkers. Not routine clinical practice.
Relevance	Target population for preventive/disease-modifying therapies.

Mild Cognitive Impairment (MCI) due to AD

Feature	Details
Cognitive Impairment	Objective impairment on neuropsychological testing (> 1.5 SD below age norms).
Subjective Complaint	Patient and/or informant report cognitive decline.
Functional Status	Independence in ADLs preserved. May have subtle IADL difficulties (complex tasks).
Not Demented	Does not meet criteria for dementia.
Subtypes	Amnestic MCI (single domain): Memory only - High risk of AD. Amnestic MCI (multiple domains): Memory + other domains. Non-amnestic MCI: Other domains without memory - Lower risk of AD.
Progression	~10-15% per year convert to AD dementia. Cumulative: ~50% by 5 years. Some remain stable or revert to normal. [21]

Mild AD (Early Dementia)

Domain	Features
Memory	Prominent recent (episodic) memory loss. Difficulty encoding new information. Forgets conversations, appointments. Repetitive questioning. Loses personal items frequently. Remote memory relatively preserved early.
Language	Word-finding difficulties (anomia). Circumlocution ("the thing you write with" for pen). Decreased verbal fluency. Reading and writing begin to decline.
Visuospatial	Gets lost in familiar places (navigation impairment). Difficulty judging distances. Problems with complex visual tasks (copying figures).
Executive Function	Difficulty planning, organising complex tasks. Poor judgment. Financial mismanagement.
IADL Impairment	Cannot manage finances independently. Medication errors. Difficulty using appliances, phone. Cannot drive safely.
ADL	Basic ADLs (dressing, bathing, eating) still largely intact.
BPSD	Apathy (most common). Mild depression, anxiety.
Insight	May retain some insight. Often minimises deficits (anosognosia developing).
MMSE	20-26/30.

Moderate AD (Middle Stage Dementia)

Domain	Features
Memory	Remote memory now affected. May not recognise less familiar people. Confabulation. Disorientation to time (date, day, season).
Language	Reduced spontaneous speech. Comprehension difficulties. Paraphasias. Echolalia may appear.
Visuospatial	Severe disorientation. May not recognise own home. Cannot navigate even familiar environments.
Executive Function	Severely impaired planning and judgment.
ADL Impairment	Needs supervision and assistance for most ADLs (dressing, bathing, grooming). Dressing apraxia.
BPSD	Agitation, restlessness, wandering. Delusions (often persecutory - "Someone is stealing from me"). Hallucinations (less common than in DLB). Depression. Sleep-wake cycle disturbance (sundowning).
Behavioural Changes	Aggression (verbal/physical). Repetitive behaviours. Disinhibition.
MMSE	10-20/30.

Severe AD (Late Stage Dementia)

Domain	Features
Memory	Profound memory loss. May not recognise close family members (including spouse, children). Loss of autobiographical memory.
Language	Minimal meaningful speech. Single words or phrases. Palilalia. Eventually mutism. Comprehension severely limited.
Motor	Gait disturbance, rigidity, bradykinesia (parkinsonian features). Myoclonus. Primitive reflexes (grasp, snout, rooting). Eventually bedridden.
ADL	Total dependence for all ADLs. Requires feeding assistance. Incontinence (urinary, then faecal).
Swallowing	Dysphagia develops. High risk of aspiration.
BPSD	Often reduced (patient too impaired). May have agitation to care.
Medical Complications	Pressure ulcers, contractures, recurrent infections (UTI, pneumonia), malnutrition, dehydration.
MMSE	less than 10/30 (or untestable).
Prognosis	Terminal stage. Death usually from aspiration pneumonia, sepsis, or multi-organ failure.

Symptom Domains: Detailed Features

A. Memory (Hallmark Feature)

Type	Early AD	Late AD
Episodic Memory	Severely impaired (FIRST and MOST PROMINENT). Cannot encode new memories. Forgets recent events, conversations.	Profound loss. Cannot recall any recent events.
Semantic Memory	Relatively preserved early.	Impaired late. Loss of general knowledge, vocabulary.
Working Memory	Mildly impaired early.	Severely impaired.
Remote Memory	Preserved early (Can recall childhood, early adulthood).	Affected in moderate-severe stage. May not recognise family.
Procedural Memory	Relatively preserved (Can still perform practiced motor skills).	Eventually lost.

Clinical Testing:

Cannot recall 3 words after 5 minutes (MMSE).
Impaired paragraph recall.
Poor performance on word list learning (ACE-III, MoCA).

B. Language

Feature	Manifestation
Anomia	Word-finding difficulty. "Tip of the tongue". Uses general terms ("thing"

"stuff"). | | Circumlocution | Describes object function instead of naming ("What you drink from" for cup). | | Reduced Fluency | Decreased spontaneous speech. Long pauses. | | Comprehension | Preserved early, declines in moderate stage. | | Repetition | Preserved until late. | | Reading/Writing | Decline in parallel with speech. | | Late Features | Echolalia (repeating others' words), palilalia (repeating own words), eventually mutism. |

C. Visuospatial Function

Feature	Manifestation
Navigation	Gets lost in familiar places (neighbourhood, supermarket). Cannot find way back from bathroom.
Constructional Apraxia	Cannot copy simple figures. Clock drawing test impaired (cannot place numbers correctly).
Visual Agnosia	Difficulty recognising faces (prosopagnosia), objects in late stage.
Driving	Unsafe - Cannot judge distances, navigate, react appropriately.

D. Executive Function

Feature	Manifestation
Planning	Cannot plan meals, trips, appointments.
Organisation	Disorganised approach to tasks.
Judgment	Poor decisions (financial, safety). Scams.
Problem-Solving	Cannot troubleshoot simple issues.
Multitasking	Cannot manage multiple tasks simultaneously.

E. Behavioural and Psychological Symptoms of Dementia (BPSD)

Prevalence: Up to 90% of AD patients experience BPSD at some point. [22]

Symptom	Frequency	Features
Apathy	70%	Lack of motivation, initiative, interest. Sits passively. Most common BPSD.
Depression	40-50%	Low mood, anhedonia, withdrawal. May predate cognitive symptoms.
Anxiety	40%	Excessive worry, restlessness. May manifest as shadowing carer.
Agitation	40-60%	Restlessness, pacing, verbal outbursts, physical aggression.
Wandering	30-40%	Aimless walking. Risk of getting lost, injury. Often worse at night.
Delusions	30-40%	Persecutory delusions common ("People are stealing from me"). Capgras syndrome (familiar person replaced by imposter).
Hallucinations	10-25%	Less common than in DLB. Usually visual.
Disinhibition	20-30%	Inappropriate comments, undressing in public, hypersexuality.
Sleep Disturbance	40%	Insomnia, day-night reversal, sundowning (worsening in evening).
Repetitive Behaviours	30%	Repetitive questioning, pacing, rummaging.

Sundowning: Worsening of confusion, agitation, and behavioural disturbance in late afternoon/evening. Affects ~20% of AD patients.

6. Investigations

Diagnostic Approach: NIA-AA Criteria for AD Dementia

Core Clinical Criteria (Probable AD Dementia): [5]

Dementia: Interference with ability to function at work or usual activities.
Insidious onset: Gradual, not sudden.
Clear history of worsening cognition (by report or observation).
Initial and most prominent cognitive deficits in ONE of:
- Amnestic presentation (most common): Memory impairment plus at least one other domain.
- Non-amnestic: Language, visuospatial, or executive presentation.
Exclusion criteria: No evidence of substantial vascular disease, DLB, FTD, other neurological/systemic disease, or medication effect sufficient to explain cognitive decline.

Probable AD with Biomarker Evidence:

Clinical criteria PLUS positive biomarkers (amyloid PET, CSF Aβ42 low, tau high).
Increases diagnostic certainty.

Cognitive Assessment Tools

Tool	Max Score	Cut-off	Domains Assessed	Notes
MMSE (Mini-Mental State Examination)	30	less than 24 suggests dementia (adjust for age/education)	Orientation, attention, memory, language, visuospatial.	Quick screen. Ceiling effect (misses mild). Copyright restrictions.
ACE-III (Addenbrooke's Cognitive Examination)	100	less than 88 (dementia), less than 82 (higher specificity)	Attention, memory, fluency, language, visuospatial (5 domains).	More sensitive than MMSE. Free to use. Takes 15-20 min.
MoCA (Montreal Cognitive Assessment)	30	less than 26 suggests impairment	Executive, visuospatial, memory, attention, language, orientation.	Sensitive for MCI. Add 1 point if education ≤12 years.
Clock Drawing Test	Various scoring	Impairment if cannot complete	Visuospatial, executive, praxis.	Quick screen. Impaired in AD, also frontal/parietal lesions.
Verbal Fluency	Number of words in 60s	Reduced	Semantic (category) and phonemic (letter) fluency.	Semantic fluency (animals, fruits) particularly affected in AD.

Limitations of Cognitive Tests:

Education: Low education may score lower without dementia (Adjust norms).
Ceiling Effect: MMSE not sensitive for mild impairment or highly educated individuals.
Language/Culture: Tests may not be appropriate for non-English speakers or different cultures.
Practice Effects: Repeat testing may show improvement due to familiarity.

Formal Neuropsychological Testing:

Specialist assessment by neuropsychologist.
Comprehensive battery (2-4 hours).
Useful for: Subtle impairment (MCI), young patients, medico-legal, atypical presentations.

Blood Tests: Exclude Reversible Causes

Essential Bloods (All patients with suspected dementia):

Test	Purpose	Reversible Cause
Full Blood Count (FBC)	Anaemia (impairs cognition).	Anaemia (B12, folate, iron deficiency).
Urea & Electrolytes (U&E)	Hyponatraemia, hypernatraemia, renal impairment.	Metabolic encephalopathy.
Liver Function Tests (LFTs)	Hepatic encephalopathy.	Liver failure, alcohol-related.
Thyroid Function (TSH, Free T4)	Hypothyroidism (cognitive slowing).	Hypothyroidism (reversible with levothyroxine).
Vitamin B12 and Folate	Deficiency → Dementia.	B12 deficiency (reversible if treated early).
Calcium	Hypercalcaemia (confusion).	Hyperparathyroidism, malignancy.
Glucose (HbA1c)	Hypoglycaemia, poorly controlled diabetes.	Diabetes.
Inflammatory Markers (CRP, ESR)	If suspicion of vasculitis, infection.	Vasculitis, chronic infection.

Additional Tests (If indicated by history/examination):

Test	Indication
Syphilis Serology (VDRL, TPPA)	Risk factors for neurosyphilis (rare but reversible).
HIV Test	Risk factors. HIV-associated dementia.
Autoimmune Screen (ANA, ANCA, anti-TPO)	Suspicion of autoimmune encephalitis.
Serum ACE, Lysozyme	Suspicion of neurosarcoidosis.
Copper, Caeruloplasmin	Young patient - Wilson's disease.
Lactate, Pyruvate	Mitochondrial disease (rare, young onset).

Neuroimaging

Structural Imaging (MRI Brain - Preferred)

Sequence	Findings in AD	Purpose
T1-Weighted	Bilateral hippocampal atrophy (most characteristic). Medial temporal lobe atrophy (Entorhinal cortex, parahippocampal gyrus). Cortical atrophy (temporoparietal > frontal early). Enlarged ventricles (ex-vacuo).	Atrophy assessment.
T2/FLAIR	Exclude vascular lesions, tumours, subdural haematomas. White matter hyperintensities (mild - age-related; extensive - consider vascular dementia).	Exclude other pathology.
Coronal T1	Best visualises hippocampal volumes and medial temporal lobe atrophy.	Hippocampal assessment.

Visual Rating Scales for Atrophy:

Medial Temporal Lobe Atrophy (MTA) Score (Scheltens Scale): 0-4 scale. Score ≥2 (age > 75) or ≥1.5 (age less than 75) suggests AD.
Global Cortical Atrophy (GCA) Scale.
Posterior Atrophy Score.

MRI vs CT:

MRI: Superior for assessing hippocampal atrophy, excluding other pathology. Preferred.
CT Brain: Acceptable if MRI contraindicated (pacemaker, claustrophobia). Shows gross atrophy but less sensitive for early/subtle changes.

Typical AD Imaging Pattern:

Early: Medial temporal (hippocampal) atrophy.
Moderate: Temporoparietal atrophy.
Late: Generalised cortical atrophy. Frontal involvement.
Spared: Primary motor cortex, primary sensory cortex, occipital cortex (until very late).

Differential Imaging Patterns:

Condition	Imaging Pattern
AD	Hippocampal + temporoparietal atrophy. Relatively symmetric.
FTD (behavioural variant)	Frontal and/or anterior temporal atrophy.
FTD (semantic variant PPA)	Asymmetric anterior temporal atrophy.
DLB	Relative preservation of medial temporal lobes. Occipital hypoperfusion (SPECT).
Vascular Dementia	Multiple infarcts, strategic strokes (thalamus, basal ganglia), extensive white matter disease.
NPH	Ventriculomegaly out of proportion to sulcal atrophy.

Functional and Molecular Imaging (Specialist Use)

Modality	Findings in AD	Clinical Use
FDG-PET	Hypometabolism (reduced glucose uptake) in temporoparietal cortex. Posterior cingulate cortex (precuneus) involved early. Frontal involvement in late stage.	Differentiate AD from FTD. Research.
Amyloid PET (Florbetapir, Florbetaben, Flutemetamol)	Positive amyloid signal (plaque binding). Positive in AD, also in some elderly without dementia.	Confirms amyloid pathology. Used in specialist/research settings. Negative scan excludes AD. Positive does not confirm AD diagnosis alone.
Tau PET	Maps distribution of tau tangles. Correlates better with cognitive decline than amyloid PET.	Research. Not routine clinical use.
SPECT (Perfusion Imaging)	Hypoperfusion in temporoparietal regions in AD.	Less commonly used (FDG-PET preferred if available).
DaTscan (Dopamine Transporter Scan)	Normal in AD. Abnormal in DLB/PDD (reduced striatal uptake).	Differentiate AD from DLB.

Cerebrospinal Fluid (CSF) Biomarkers (Specialist - Not Routine)

Indications: Atypical presentation, young onset (less than 65), diagnostic uncertainty, research.

Biomarker	AD Pattern	Interpretation
Aβ42 (Amyloid-beta 42)	Decreased	Aβ42 sequestered in plaques → Low CSF levels.
Total Tau (t-tau)	Increased	Neuronal injury/death → Tau released into CSF.
Phosphorylated Tau (p-tau)	Increased	Specific for tangle pathology. Better specificity for AD than t-tau.
Aβ42/Aβ40 Ratio	Decreased	More robust than Aβ42 alone.

AD CSF Signature: Low Aβ42 + High t-tau + High p-tau.

Sensitivity/Specificity: ~85-90% for AD vs controls. Useful in specialist memory clinics.

Limitations:

Lumbar puncture required (invasive, patient anxiety).
Not widely available outside specialist centres.
Abnormalities can occur in asymptomatic elderly (preclinical AD).
Less useful in very elderly (high background positivity).

Other Investigations

Test	Indication
EEG	Atypical features, suspected CJD (periodic sharp wave complexes), seizures. Normal or mild slowing in AD.
Genetic Testing	Early-onset AD (less than 65): Consider APP, PSEN1, PSEN2 testing if strong family history (autosomal dominant pattern). APOE genotyping: NOT recommended for routine diagnosis (risk factor, not deterministic). May be used in research.
Brain Biopsy	Extremely rare. Only if suspicion of inflammatory, infectious, or neoplastic process mimicking dementia.

7. Management

Principles of Management

No Cure: Current treatments are symptomatic, not disease-modifying.
Holistic Approach: Pharmacological + Non-pharmacological + Carer support.
Multidisciplinary Team: Physicians, nurses, occupational therapists, physiotherapists, social workers, psychologists.
Person-Centred Care: Respect autonomy, dignity, preferences.
Advance Care Planning: Early discussions about future care, DNAR, end-of-life wishes.

Management Algorithm

SUSPECTED ALZHEIMER'S DISEASE
(Gradual memory decline, elderly patient)
                    ↓
┌────────────────────────────────────────────────────────────┐
│ STEP 1: INITIAL ASSESSMENT (Primary Care)                 │
│ - Detailed history (patient + collateral from family)     │
│ - Cognitive screening (MMSE, ACE-III, MoCA, Clock Drawing)│
│ - Physical examination (neurological, cardiovascular)     │
│ - Blood tests (FBC, U&E, LFTs, TFTs, B12, folate, glucose,│
│   calcium) - EXCLUDE REVERSIBLE CAUSES                    │
│ - Consider MRI Brain                                       │
└────────────────────────────────────────────────────────────┘
                    ↓
┌────────────────────────────────────────────────────────────┐
│ STEP 2: REFERRAL TO SPECIALIST (Memory Clinic)            │
│ - Geriatrician, Neurologist, or Psychiatrist              │
│ - Comprehensive cognitive assessment                      │
│ - Review imaging (MRI - hippocampal atrophy)              │
│ - Exclude other dementias (DLB, FTD, vascular)            │
│ - Confirm diagnosis: PROBABLE AD                          │
└────────────────────────────────────────────────────────────┘
                    ↓
┌────────────────────────────────────────────────────────────┐
│ STEP 3: PHARMACOLOGICAL MANAGEMENT                        │
│                                                            │
│ MILD-TO-MODERATE AD (MMSE 10-26):                         │
│ ═══════════════════════════════════════════                │
│ ACETYLCHOLINESTERASE INHIBITORS (AChEIs)                  │
│                                                            │
│ Option 1: **DONEPEZIL** (First-line - Most commonly used) │
│   - Start: 5mg once daily (at night)                      │
│   - Increase after 4-6 weeks: 10mg once daily             │
│   - Max: 10mg (23mg formulation exists but limited use)   │
│                                                            │
│ Option 2: **RIVASTIGMINE**                                │
│   - Patch (preferred): Start 4.6mg/24h, increase to       │
│     9.5mg/24h after 4 weeks. Max: 13.3mg/24h              │
│   - Oral: 1.5mg BD, increase to 3-6mg BD (more GI SEs)    │
│                                                            │
│ Option 3: **GALANTAMINE**                                 │
│   - Modified release: Start 8mg OD, increase to 16mg OD   │
│     after 4 weeks. Max: 24mg OD                           │
│   - Immediate release: Start 4mg BD, titrate to 12mg BD   │
│                                                            │
│ MONITORING:                                                │
│ - Assess response at 3-6 months (Cognition, function,     │
│   global impression)                                       │
│ - Continue if beneficial (stabilisation or slowing decline)│
│ - Stop if no benefit or intolerable side effects          │
│                                                            │
│ ────────────────────────────────────────────────────────── │
│                                                            │
│ MODERATE-TO-SEVERE AD (MMSE less than 10-20):                      │
│ ═══════════════════════════════════════════                │
│                                                            │
│ Option 1: **Continue AChEI** (if already on and tolerated)│
│           PLUS                                             │
│           **MEMANTINE** (NMDA receptor antagonist)        │
│   - Start: 5mg once daily                                 │
│   - Increase weekly by 5mg to target: 20mg once daily     │
│     (Can give as 10mg BD or 20mg OD)                      │
│                                                            │
│ Option 2: **MEMANTINE monotherapy**                       │
│           (If AChEI not tolerated or contraindicated)     │
│                                                            │
│ COMBINATION THERAPY (AChEI + Memantine):                  │
│ - Evidence supports modest additional benefit             │
│ - NICE approved for moderate-severe AD                    │
│                                                            │
└────────────────────────────────────────────────────────────┘
                    ↓
┌────────────────────────────────────────────────────────────┐
│ STEP 4: NON-PHARMACOLOGICAL MANAGEMENT                    │
│                                                            │
│ COGNITIVE INTERVENTIONS:                                   │
│ - **Cognitive Stimulation Therapy (CST)**: Group sessions,│
│   structured activities, social interaction. Evidence-based│
│ - Cognitive rehabilitation (individualised)               │
│ - Reality orientation                                      │
│ - Reminiscence therapy (life story work)                  │
│                                                            │
│ PHYSICAL ACTIVITY:                                         │
│ - Regular aerobic exercise (walking, swimming)            │
│ - Reduces decline, improves mood, cardiovascular health   │
│                                                            │
│ OCCUPATIONAL THERAPY:                                      │
│ - ADL adaptations (simplify environment, labels, routines)│
│ - Home safety assessment (remove hazards, falls risk)     │
│ - Assistive devices                                        │
│                                                            │
│ OTHER INTERVENTIONS:                                       │
│ - Music therapy, art therapy, pet therapy                 │
│ - Multisensory stimulation (Snoezelen)                    │
│ - Maintain social engagement                              │
│                                                            │
└────────────────────────────────────────────────────────────┘
                    ↓
┌────────────────────────────────────────────────────────────┐
│ STEP 5: BPSD (Behavioural \& Psychological Symptoms)      │
│         MANAGEMENT                                         │
│                                                            │
│ PRINCIPLES:                                                │
│ 1. Identify and treat UNDERLYING CAUSES:                  │
│    - Pain (MSK, constipation, urinary retention)          │
│    - Infection (UTI, pneumonia)                            │
│    - Medication side effects                              │
│    - Environmental triggers (noise, overstimulation)      │
│    - Unmet needs (hunger, thirst, toileting, boredom)     │
│                                                            │
│ 2. NON-PHARMACOLOGICAL FIRST:                              │
│    - Environmental modification (calm, structured)        │
│    - Distraction, redirection                             │
│    - Validation therapy                                    │
│    - Caregiver education and support                      │
│    - Music, activities                                     │
│                                                            │
│ 3. PHARMACOLOGICAL (If severe, distressing, or safety risk│
│    AND non-pharm failed):                                 │
│                                                            │
│    DEPRESSION/ANXIETY:                                     │
│    - SSRIs (Citalopram, Sertraline) - First-line          │
│    - Mirtazapine (if insomnia)                            │
│                                                            │
│    AGITATION/AGGRESSION/PSYCHOSIS:                         │
│    - **AVOID ANTIPSYCHOTICS if possible**                 │
│      (Increased stroke risk, mortality in dementia)       │
│    - If essential (severe, risk to self/others):          │
│      * Risperidone 0.25-1mg (Licensed for short-term use  │
│        in severe aggression in AD)                        │
│      * Haloperidol, Olanzapine, Quetiapine (off-label)    │
│      * Use LOWEST dose, SHORTEST duration                 │
│      * Review every 6 weeks, aim to withdraw              │
│    - Memantine may help BPSD                              │
│                                                            │
│    SLEEP DISTURBANCE:                                      │
│    - Sleep hygiene, daytime activity                      │
│    - Melatonin (if circadian dysregulation)               │
│    - Avoid benzodiazepines (paradoxical agitation, falls) │
│                                                            │
└────────────────────────────────────────────────────────────┘
                    ↓
┌────────────────────────────────────────────────────────────┐
│ STEP 6: CARER SUPPORT                                     │
│                                                            │
│ - Psychoeducation (disease course, management strategies) │
│ - Carer support groups                                     │
│ - Respite care (day centres, residential respite)         │
│ - Financial support (Attendance Allowance, Carer's        │
│   Allowance, Direct Payments)                             │
│ - Address carer burnout, depression                       │
│ - Signposting to Alzheimer's Society, Age UK              │
│                                                            │
└────────────────────────────────────────────────────────────┘
                    ↓
┌────────────────────────────────────────────────────────────┐
│ STEP 7: LEGAL \& ADVANCE CARE PLANNING                    │
│                                                            │
│ EARLY STAGE (While patient has capacity):                 │
│ - **Lasting Power of Attorney (LPA)**:                    │
│   * Health \& Welfare LPA                                  │
│   * Property \& Financial Affairs LPA                      │
│ - **Advance Decision to Refuse Treatment (ADRT)**         │
│ - Discuss future care preferences (care home, CPR, DNAR)  │
│                                                            │
│ DRIVING:                                                   │
│ - Inform DVLA (legal requirement in UK)                   │
│ - DVLA assesses fitness to drive                          │
│ - May require on-road assessment                          │
│ - Many will need to stop driving (safety)                 │
│                                                            │
│ LATE STAGE:                                                │
│ - **Mental Capacity Act** assessment                      │
│ - **Best Interests** decisions if lacks capacity          │
│ - Consider DNAR (Do Not Attempt Resuscitation)            │
│ - End-of-life care planning (Palliative care input)       │
│ - ReSPECT form (Recommended Summary Plan for Emergency    │
│   Care and Treatment)                                     │
│                                                            │
└────────────────────────────────────────────────────────────┘

Pharmacological Management: Detailed

Acetylcholinesterase Inhibitors (AChEIs)

Mechanism of Action: Inhibit acetylcholinesterase enzyme → Increase synaptic acetylcholine → Enhance cholinergic neurotransmission. [7,20]

Drug	Mechanism	Dosing	Notes
DONEPEZIL	Reversible, non-competitive AChEI. Selective for CNS (less peripheral effects).	Start: 5mg OD (at night). Increase after 4-6 weeks to 10mg OD. Max: 10mg. (23mg formulation for severe AD - limited evidence, rarely used).	First-line. Most commonly prescribed. Once daily dosing. Best tolerated. Half-life 70 hours.
RIVASTIGMINE	Pseudo-irreversible AChEI. Also inhibits butyrylcholinesterase.	Patch (preferred): Start 4.6mg/24h, increase after 4 weeks to 9.5mg/24h. Max: 13.3mg/24h. Oral capsules: Start 1.5mg BD, increase every 4 weeks to 3mg BD, then 4.5mg BD, max 6mg BD.	Patch preferred (better tolerability, less GI side effects). Oral has more nausea/vomiting. Only AChEI available as patch.
GALANTAMINE	Reversible competitive AChEI. Also allosteric nicotinic receptor modulator (additional mechanism).	Modified release: Start 8mg OD (morning with food), increase after 4 weeks to 16mg OD. Max: 24mg OD. Immediate release: Start 4mg BD, increase to 8mg BD after 4 weeks, max 12mg BD.	Dual mechanism. Modified release preferred (once daily).

Efficacy: [7,8]

Modest symptomatic benefit.
Delay in cognitive decline equivalent to ~6-12 months.
May stabilise function, improve BPSD.
Do NOT halt disease progression - neurons continue to die.
Effect size: ~2-3 point improvement on ADAS-Cog (cognitive scale) vs placebo.
~40-50% "responders" show meaningful benefit.

Side Effects: [7]

System	Side Effects	Management
Gastrointestinal (Most common)	Nausea, vomiting, diarrhoea, anorexia, weight loss. Usually transient (first 2-4 weeks).	Give with food. Slow titration. Rivastigmine patch (less GI SEs). Antiemetics if needed (domperidone).
Cardiovascular	Bradycardia (enhanced vagal tone), Heart block, Syncope. Exacerbates sick sinus syndrome.	Check baseline ECG if cardiac history. Caution in bradycardia, AV block. Monitor pulse.
Neurological	Dizziness, headache, insomnia, vivid dreams/nightmares.	Donepezil: Give in morning if insomnia/vivid dreams (instead of night).
Urinary	Urinary frequency, incontinence (increased bladder contractility).	Caution in bladder outflow obstruction.
Respiratory	Bronchospasm (cholinergic effect).	Caution in asthma, COPD.
Other	Muscle cramps, fatigue.	Usually mild.

Contraindications:

Known hypersensitivity.
Caution in: Bradycardia (less than 60 bpm), sick sinus syndrome, AV block, cardiac conduction disorders, asthma/COPD (severe), active peptic ulcer, bladder outflow obstruction.

Interactions:

Beta-blockers: Increased bradycardia risk.
Anticholinergics (e.g., oxybutynin, amitriptyline): Antagonise AChEI effect. Avoid if possible.
NSAIDs: Increased peptic ulcer risk.

Monitoring:

Assess response at 3-6 months: Cognition (repeat MMSE/ACE-III), function (ADL assessment), global impression (clinician and carer).
Continue if benefit (stabilisation or slower decline counts as benefit).
Discontinue if: No benefit, intolerable side effects, patient/carer wishes, severe/terminal stage (no meaningful benefit).

Switching AChEIs:

If poor tolerability or inadequate response, can switch to alternative AChEI.
No clear evidence one is superior, but individual responses vary.

Memantine

Mechanism of Action: Non-competitive NMDA receptor antagonist. Blocks excessive glutamate activity (glutamate excitotoxicity) while permitting physiological NMDA receptor activity. [7,8]

Aspect	Details
Indication	Moderate-to-severe AD (MMSE less than 20). Can combine with AChEI or use as monotherapy.
Dosing	Start: 5mg once daily (morning). Increase weekly by 5mg increments: Week 1: 5mg OD Week 2: 10mg OD (or 5mg BD) Week 3: 15mg (10mg morning + 5mg evening) Week 4: 20mg OD (or 10mg BD) Target: 20mg/day. Renal impairment: Reduce dose if eGFR less than 30.
Efficacy	Modest benefit in moderate-severe AD. Delays functional decline. May reduce BPSD. Effect size smaller than AChEIs. Combination with AChEI shows additive benefit. [7,8]
Side Effects	Generally well-tolerated. CNS: Dizziness, headache, confusion (uncommon), hallucinations (rare). GI: Constipation. Other: Fatigue, hypertension (slight). Fewer side effects than AChEIs.
Contraindications	Severe renal impairment (eGFR less than 5). Caution in epilepsy (may lower seizure threshold).

Combination Therapy (AChEI + Memantine):

NICE recommends for moderate-severe AD.
Evidence supports modest additive benefit over monotherapy. [7]
Targets two different pathways: Cholinergic (AChEI) + Glutamatergic (Memantine).

When to Stop Medications

Consider Stopping if:

No benefit after 3-6 month trial (decline same as expected natural history).
Intolerable side effects.
Severe/terminal stage (MMSE less than 5, bedbound, non-verbal) - medications unlikely to provide meaningful benefit.
Patient/carer preference.
Adverse event (e.g., bradycardia, syncope).

How to Stop:

Can stop abruptly (no withdrawal syndrome).
Some clinicians taper to monitor for worsening (but not necessary).

Emerging Disease-Modifying Therapies

Anti-Amyloid Monoclonal Antibodies [9,10]

Drug	Mechanism	Trial Results	Regulatory Status	Key Considerations
Lecanemab (Leqembi)	Humanised IgG1 monoclonal antibody targeting soluble Aβ protofibrils. IV infusion every 2 weeks.	CLARITY-AD trial: 27% slower decline on CDR-SB (global function) vs placebo over 18 months in early AD (MCI due to AD or mild AD). Statistically significant but modest clinical effect. [9]	FDA approved (Jan 2023). MHRA approved (UK, 2024). NICE: Under appraisal (cost-effectiveness concerns).	Requires IV infusion Q2W. Amyloid PET or CSF confirmation needed. Risk of ARIA.
Donanemab (Kisunla)	Humanised IgG1 against N-terminal pyroglutamate Aβ. IV infusion every 4 weeks.	TRAILBLAZER-ALZ 2: 22-35% slower decline on iADRS (integrated AD Rating Scale) vs placebo in early AD. [10]	FDA approved (Jul 2024). NICE: Under review.	Similar efficacy to lecanemab. Monthly infusion. ARIA risk.
Aducanumab (Aduhelm)	Anti-Aβ antibody.	Controversial approval (FDA 2021) - conflicting trial results. Limited use. High cost.	FDA approved but restricted use. Not approved in EU/UK.	Largely abandoned due to unclear benefit and ARIA risk.

Amyloid-Related Imaging Abnormalities (ARIA):

ARIA-E (Oedema): Vasogenic oedema. Usually asymptomatic. ~13-17% with lecanemab/donanemab.
ARIA-H (Haemorrhage): Microhaemorrhages, superficial siderosis. ~10-15%.
Monitoring: MRI scans required before treatment, during treatment (months 3, 6, 9, 12, etc.).
Risk factors: APOE ε4 homozygotes (highest risk), anticoagulation.
Most ARIA is asymptomatic and resolves, but can be serious (rare).

Eligibility Criteria (Typical):

Early AD (MCI due to AD or mild AD dementia).
Confirmed amyloid pathology (PET or CSF).
MMSE ~20-30 (varies by trial/approval).
No significant cerebrovascular disease.
Able to undergo regular IV infusions and MRI monitoring.

Challenges:

Modest clinical benefit: Statistically significant but small effect size. Unclear if clinically meaningful.
Cost: Very high (£20,000-30,000/year).
Infrastructure: Requires amyloid confirmation (PET/CSF), IV infusion centres, MRI monitoring.
ARIA risk: Need for safety monitoring.
NICE hesitancy: Cost-effectiveness thresholds not met in UK.

Future Directions:

Earlier intervention (preclinical AD).
Combination therapies (anti-amyloid + anti-tau).
Oral formulations.
Biomarker-guided precision medicine.

Non-Pharmacological Management

Evidence-Based Non-Pharmacological Interventions: [18,22]

Intervention	Evidence	Implementation
Cognitive Stimulation Therapy (CST)	Strongest evidence. Group-based structured activities. Improves cognition and quality of life comparable to AChEIs.	14-session programme (biweekly). Themes (childhood, food, current affairs). Social interaction. Available in memory clinics, community centres.
Cognitive Rehabilitation	Individualised, goal-oriented. Helps maintain function in meaningful activities.	Occupational therapist-led. Focus on personally relevant tasks.
Reminiscence Therapy	Uses past memories (photos, music, objects) to stimulate discussion. Improves mood, QoL.	Life story work. Memory boxes. Group or individual.
Physical Exercise	Aerobic exercise (walking, swimming, cycling). Reduces decline, improves cardiovascular health, mood.	150 min/week moderate activity. Group classes beneficial (social).
Music Therapy	Listening, singing, playing instruments. Engages preserved musical memory. Reduces agitation, improves mood.	Personalised playlists. Group singing.
Occupational Therapy	ADL adaptations. Simplify environment (labels, routines). Home safety assessment (remove trip hazards). Assistive devices.	OT home visit. Practical strategies for daily living.
Multisensory Stimulation (Snoezelen)	Controlled multisensory environment (lights, sounds, textures). Reduces agitation in some.	Specialist rooms. Limited availability.

Interventions with Limited/No Evidence:

Ginkgo biloba: No evidence of benefit. [18]
Vitamin E: No benefit, possible harm at high doses. [18]
Omega-3 supplements: No benefit in established AD (may help prevention). [18]

Carer Support

Carer Burden in Dementia: [22]

70% of dementia care provided by informal carers (family, friends).
High rates of carer depression (40-50%), anxiety, burnout.
Reduced quality of life, physical health problems.

Support Strategies: | Intervention | Details | |--------------|---------|| | Psychoeducation | Teach about AD (disease course, symptoms, management). Realistic expectations. | | Carer Training | Communication strategies. Behaviour management. ADL assistance techniques. | | Support Groups | Peer support. Share experiences. Alzheimer's Society, Dementia UK. | | Respite Care | Day centres, sitting services, short residential stays. Give carer breaks. | | Psychological Therapy | CBT, counselling for carer depression/anxiety. | | Financial Support | Attendance Allowance (for patient), Carer's Allowance, Council Tax reduction, Direct Payments. | | Admiral Nurses | Specialist dementia nurses supporting families (Dementia UK charity). |

Treatment Monitoring and Discontinuation

When to Stop AChEIs/Memantine

Consider Stopping if:

No benefit after 3-6 month trial (decline same as expected natural history).
Intolerable side effects (persistent GI symptoms, bradycardia, syncope).
Severe/terminal stage (MMSE \u003c5, bedbound, non-verbal, end-of-life) - medications unlikely to provide meaningful benefit. Focus shifts to palliative care.
Patient/carer preference (informed decision to discontinue).
Adverse event requiring cessation.

How to Stop:

Can stop abruptly (no withdrawal syndrome for AChEIs or memantine).
Some clinicians taper over 1-2 weeks to monitor for acute worsening (not necessary).
Document decision and rationale.
Reassess - if worsening noted after stopping, can consider restarting.

Assessing Treatment Response

3-6 Month Review after initiating AChEI/memantine:

Domain	Assessment Tool	Response Indicator
Cognition	Repeat MMSE/ACE-III/MoCA	Improvement OR stabilisation (no decline) OR slower decline than expected. \u003cbr\u003e Expected decline: ~3-4 MMSE points/year untreated. If only lost 1-2 points over 6 months → Treatment benefit.
Function	BADL/IADL scales (e.g., Barthel Index, Lawton IADL scale)	Maintained independence in ADLs/IADLs OR slower functional decline.
Behaviour	NPI (Neuropsychiatric Inventory)	Reduced BPSD (agitation, apathy, depression).
Global Impression	CIBIC+ (Clinician Interview-Based Impression of Change plus caregiver input)	Clinician and carer report overall impression: Better, Same, or Worse.
Quality of Life	QoL-AD scale	Patient and carer-rated quality of life.

Interpretation:

Responder: Improvement or stabilisation in any domain = Continue treatment.
Stabilisation counts as success (natural history is progressive decline).
Non-responder: Continued decline at expected rate across all domains + no carer-perceived benefit = Consider stopping.

Long-Term Monitoring:

Review every 6-12 months once stable on treatment.
Monitor for side effects (pulse, weight, GI symptoms).
Reassess benefit-burden ratio as disease progresses.

8. Complications

Complication	Frequency	Pathophysiology	Management
Falls and Fractures	Very common	Gait instability, visuospatial impairment, impaired judgment, medication side effects (sedatives, orthostatic hypotension).	Physiotherapy, home safety modifications, hip protectors, bone health (vitamin D, calcium, bisphosphonates if osteoporosis).
Aspiration Pneumonia	Leading cause of death	Dysphagia (swallowing dysfunction), impaired cough reflex, silent aspiration. Bedridden → Hypostatic pneumonia.	Speech therapy assessment. Modified diet (thickened fluids, puree). Upright positioning during feeding. Oral hygiene. Antibiotics for pneumonia. Consider end-of-life care discussions.
Pressure Ulcers	Common in late stage	Immobility, malnutrition, incontinence. Bedridden patients.	Frequent repositioning (2-hourly). Pressure-relieving mattress. Skin care. Nutrition. Tissue viability nurse input.
Malnutrition and Dehydration	Very common	Forgetting to eat/drink. Difficulty feeding self. Dysphagia. Loss of appetite. Agitation at mealtimes.	Feeding assistance. High-calorie supplements (Fortisip, Ensure). Encourage oral intake. Consider NG feeding (ethical considerations in advanced dementia).
Urinary Tract Infections (UTI)	Very common	Urinary incontinence, catheterisation, poor hygiene, incomplete bladder emptying.	Hydration. Hygiene. Treat infections. Avoid unnecessary catheterisation.
Constipation and Faecal Impaction	Very common	Immobility, poor fluid intake, medications (opiates, anticholinergics), reduced dietary fibre.	Laxatives (senna, lactulose, macrogol). Adequate fluids. Mobility. Disimpaction if needed (manual evacuation, enemas).
Wandering and Getting Lost	30-40%	Disorientation, memory loss, restlessness.	Supervised environment. Door alarms. GPS trackers. Safe Return scheme (Alzheimer's Society). ID bracelets.
Behavioural Disturbance	Up to 90%	See BPSD. Agitation, aggression, sundowning.	Non-pharm management. Identify triggers. Pharmacological if severe (see BPSD section).
Carer Burnout	40-50% of carers	Chronic stress, physical and emotional demands, lack of support, social isolation.	Respite care, support groups, counselling, financial support. Early recognition.
Institutional Care (Care Home Placement)	Majority eventually	Disease progression, high care needs, carer inability to cope, safety concerns.	Advance planning. Financial assessment (self-funded vs local authority). Choose appropriate care home (dementia-specialist preferred).
Seizures	10-20% (late stage)	Neuronal loss, cortical damage.	Antiepileptic drugs (levetiracetam, lamotrigine - avoid enzyme inducers). Safety measures.
Depression and Apathy	40-50%	Comorbid depression, awareness of deficits, neurodegeneration (frontal circuits).	SSRIs (citalopram, sertraline). Non-pharm (activity, social engagement).
Death	100% (terminal disease)	Usually from: Aspiration pneumonia (most common), Sepsis (UTI, pressure ulcers), Falls/fractures, multi-organ failure.	Palliative care approach. DNAR discussions. Comfort-focused care. Anticipatory medications (pain, secretions, agitation). Family support.

9. Prognosis and Outcomes

Survival

Factor	Data
Median Survival from Symptom Onset	8-10 years (Range: 3-20 years). [2]
Median Survival from Diagnosis	4-5 years (Diagnosis usually 3-5 years after symptom onset). [2]
Stage-Specific Survival	Mild AD: 5-7 years. Moderate AD: 3-5 years. Severe AD: 1-3 years.
Age at Diagnosis	Younger onset → Longer survival (more physiological reserve). Very elderly (> 85) → Shorter survival (comorbidities).

Factors Affecting Prognosis

Factor	Effect on Prognosis
Age at onset	Younger onset: Faster cognitive decline, longer overall survival. Older onset: Slower decline but shorter survival (comorbidities).
APOE ε4	ε4 carriers: Faster progression, shorter survival. [14]
Sex	Men: Faster progression and shorter survival than women. [12]
Education	Higher education: Slower apparent decline (cognitive reserve), but faster decline once symptoms appear (steeper trajectory). [18]
Comorbidities	Cardiovascular disease, diabetes: Faster decline.
BPSD	Severe BPSD: Faster progression, earlier institutionalisation.
Functional decline	Rapid ADL loss: Poorer prognosis.

Progression Rate

Variable: Some decline slowly over 15+ years, others rapidly over 3-5 years.
Average: ~3-4 point decline on MMSE per year (untreated).
Stages:
- "MCI to Mild AD: 2-5 years."
- "Mild to Moderate: 2-3 years."
- "Moderate to Severe: 2-3 years."
- "Severe to Death: 1-2 years."

Cause of Death

Cause	Frequency
Aspiration Pneumonia	40-50% (Most common)
Other Infections (UTI, sepsis)	20-30%
Cardiovascular Events (MI, stroke)	10-15%
Falls/Fractures (Hip fracture → Complications)	5-10%
Multi-organ Failure	Late stage immobility, malnutrition, pressure ulcers.

Quality of Life

Progressive decline in QoL as disease advances.
Moderate stage: Loss of independence, awareness of deficits → Distress.
Severe stage: Reduced awareness may paradoxically reduce distress, but total dependence and medical complications dominate.

Effect of Treatment on Prognosis

AChEIs and Memantine: Delay cognitive and functional decline by ~6-12 months. Do NOT alter disease course or survival.
Anti-amyloid therapies (Lecanemab, Donanemab): Modest slowing of decline (~27%) in early AD. Long-term impact on survival unknown.

10. Evidence and Guidelines

Key Guidelines

Guideline	Organisation	Year	Key Recommendations
Dementia: Assessment, Management and Support for People Living with Dementia and Their Carers (NG97)	NICE (UK)	2018	- AChEIs (donepezil, rivastigmine, galantamine) for mild-moderate AD. - Memantine for moderate-severe AD (monotherapy or add to AChEI). - Cognitive stimulation therapy (CST). - Avoid antipsychotics unless severe distress/risk. - Non-pharm interventions first for BPSD. [7]
NIA-AA Diagnostic Guidelines for Alzheimer's Disease	NIA-AA (USA)	2011 (Updated 2018)	- Clinical criteria for probable AD. - Research framework incorporating biomarkers (A/T/N: Amyloid/Tau/Neurodegeneration). - Preclinical AD, MCI due to AD, AD dementia stages. [5]
Alzheimer's Association Guidelines	Alzheimer's Association	Ongoing	- Early detection, biomarker use, comprehensive care. - Support for anti-amyloid therapies in early AD.
World Alzheimer Report	Alzheimer's Disease International	Annual	- Global burden, prevalence projections, risk reduction strategies. [11]
European Guidelines on Dementia	EFNS/ENS	2012	- Similar to NICE. AChEIs and memantine. Non-pharm interventions.

Landmark Trials and Evidence

AChEI Trials

Trial/Meta-Analysis	Findings
Cochrane Review - Donepezil for AD (2018)	Benefit in cognition (ADAS-Cog ~2-3 points), function, global impression in mild-moderate and severe AD. NNT ~7 for improvement. Side effects: GI, bradycardia. [7]
Cochrane Review - Rivastigmine for AD (2015)	Similar efficacy to donepezil. Oral formulation more GI side effects; patch better tolerated. [7]
Cochrane Review - Galantamine for AD (2019)	Modest benefit in cognition, function, behaviour. Similar efficacy to other AChEIs. [7]

Memantine Trials

Trial/Meta-Analysis	Findings
Cochrane Review - Memantine for AD (2019)	Benefit in moderate-severe AD (cognition, function, BPSD). Small effect size. Well-tolerated. Combination with AChEI shows additive benefit. [8]

Anti-Amyloid Antibody Trials

Trial	Drug	Findings
CLARITY-AD (2023)	Lecanemab	27% slower decline on CDR-SB (global function) vs placebo in early AD over 18 months. Statistical significance (pless than 0.001). Effect size modest. ARIA-E in 12.6%. [9]
TRAILBLAZER-ALZ 2 (2023)	Donanemab	22-35% slower decline on iADRS vs placebo in early AD. Low/medium tau participants showed greater benefit. ARIA in ~24%. [10]

Risk Reduction Evidence

Lancet Commission on Dementia Prevention (2020): [16]

Identified 12 modifiable risk factors accounting for ~40% of dementia cases worldwide.
Life-course approach: Early life (education), Midlife (hearing loss, TBI, hypertension, obesity, alcohol), Later life (smoking, depression, social isolation, physical inactivity, diabetes, air pollution).

20. Patient and Layperson Explanation

What is Alzheimer's Disease?

Alzheimer's disease is a brain condition that gradually affects memory, thinking, and the ability to do everyday tasks. It is the most common cause of dementia - a term describing symptoms of memory loss and confusion.

In Alzheimer's, abnormal proteins build up in the brain, causing brain cells to die. Over time, the brain shrinks, and this leads to worsening symptoms.

What are the symptoms?

Early signs include:

Forgetting recent conversations or events.
Repeating the same questions.
Misplacing items (keys, glasses).
Getting confused about time or place.
Difficulty finding the right words.

As the disease progresses, people may:

Have trouble recognising family and friends.
Need help with dressing, eating, and washing.
Experience changes in mood or behaviour (anxiety, agitation, depression).
Become confused about where they are.

In advanced stages, people:

Need full-time care.
May lose the ability to speak or move.
Are at risk of infections and swallowing problems.

What causes Alzheimer's?

The exact cause is not fully understood, but several factors play a role:

Age: The biggest risk factor. Most people with Alzheimer's are over 65.
Genetics: A gene called APOE ε4 increases risk, but does not guarantee you will develop Alzheimer's. Rare inherited forms affect younger people (under 65).
Lifestyle: Heart health matters. High blood pressure, diabetes, smoking, obesity, and physical inactivity increase risk.

Is there a cure?

Currently, there is no cure for Alzheimer's disease. However:

Medications like Donepezil (Aricept), Rivastigmine, and Galantamine can help with symptoms for a time (usually 6-12 months benefit). They do not stop the disease progressing.
Memantine is used for moderate to severe Alzheimer's.
New treatments (Lecanemab, Donanemab) are being developed that may slow the disease slightly, but are not yet widely available in the UK.

What can help?

Non-drug approaches are very important:

Stay active - physical exercise, walking, swimming.
Keep your brain active - puzzles, reading, social activities.
Eat well - Mediterranean diet (fish, vegetables, olive oil).
Stay socially connected - avoid isolation.
Treat hearing loss - use hearing aids if needed.

For people with Alzheimer's:

Cognitive Stimulation Therapy (group activities and discussions) can help.
Routine and structure help reduce confusion.
Support from family and carers is essential.

Is it hereditary?

Most cases are NOT directly inherited. If a parent has Alzheimer's, your risk is slightly higher, but most people with a family history will NOT develop it.
Rare cases (younger onset, under 65) can be caused by specific gene mutations passed from parent to child.

Driving

If you are diagnosed with dementia, you must inform the DVLA by law. The DVLA will assess whether it is safe for you to continue driving. Many people with dementia will need to stop driving at some point for safety.

What about the future?

Alzheimer's is a progressive disease - symptoms will worsen over time.
The speed of progression varies. Some people decline slowly over many years; others more quickly.
Planning ahead is important:
- Lasting Power of Attorney (someone to make decisions for you).
- Discuss your care wishes with family.
Support is available: Alzheimer's Society, Dementia UK, Admiral Nurses, local support groups.

End of Life

In the final stages, Alzheimer's is a terminal illness. Most people die from complications like pneumonia or infections. Palliative care focuses on comfort and quality of life.

Where to get help and information?

Alzheimer's Society: alzheimers.org.uk | Helpline: 0333 150 3456
Dementia UK (Admiral Nurses): dementiauk.org | Helpline: 0800 888 6678
Age UK: ageuk.org.uk | Helpline: 0800 678 1602
NHS: nhs.uk/conditions/alzheimers-disease
DVLA: gov.uk/dementia-and-driving

12. Prevention and Risk Reduction

Evidence-Based Prevention Strategies

The Lancet Commission on Dementia Prevention (2020, 2024) identified 14 modifiable risk factors accounting for approximately 45% of dementia cases worldwide, offering substantial opportunity for primary prevention. [1,16]

Life-Course Approach to Dementia Prevention

Life Stage	Risk Factors	Preventive Interventions	Population Attributable Fraction (PAF)
Early Life (\u003c18 years)	Less education	Complete secondary education. Cognitive enrichment. Educational attainment ≥12 years.	5%
Midlife (45-65 years)	Hearing loss	Treat hearing impairment. Use hearing aids. Regular audiometry.	8%
	Traumatic brain injury	Use helmets, seatbelts. Fall prevention. Avoid contact sports with repeated head trauma.	3%
	Hypertension	Target BP \u003c130/80 mmHg. Antihypertensive therapy. DASH diet.	7%
	Obesity (BMI \u003e30)	Maintain healthy weight. Mediterranean diet. Regular exercise.	1%
	Excessive alcohol	Limit to ≤14 units/week. Avoid binge drinking.	1%
Later Life (\u003e65 years)	Smoking	Smoking cessation (never too late - benefit even if quit late in life).	5%
	Depression	Early treatment with antidepressants. Psychological therapy. Social support.	3%
	Social isolation	Maintain social networks. Community engagement. Group activities.	4%
	Physical inactivity	150 min/week moderate aerobic activity (walking, swimming, cycling).	2%
	Diabetes	Glycaemic control (HbA1c \u003c7%). Lifestyle modification. Medications.	1%
	Air pollution	Reduce exposure to PM2.5 and NO2 (challenging - policy-level intervention).	2%
	Vision loss	Treat cataracts, macular degeneration. Regular optometry. Use visual aids.	2%
	High LDL cholesterol	Statin therapy if indicated. Mediterranean diet. Exercise.	1%

Total Preventable: ~45% of dementia cases theoretically preventable through addressing these 14 factors. [1,16]

Dietary Interventions

Mediterranean Diet (MedDiet)

Component	Details	Evidence
Key Foods	High: Vegetables, fruits, legumes, nuts, whole grains, olive oil (extra virgin), fish (omega-3 rich). \u003cbr\u003e Moderate: Poultry, eggs, dairy. \u003cbr\u003e Low: Red meat, processed foods, sweets.	Observational studies show 30-40% reduced AD risk with high adherence. [18]
MIND Diet	Combination of Mediterranean and DASH diets. Emphasises berries, leafy greens, nuts, fish, olive oil.	RCTs show modest cognitive benefit. Slows cognitive decline. [18]
Mechanisms	Antioxidants (polyphenols), anti-inflammatory (omega-3 fatty acids), reduced vascular risk, gut microbiome modulation.	Multiple pathways.
Recommendation	Adopt Mediterranean-style diet. Replace saturated fats with EVOO. Fish 2-3x/week. Daily nuts, vegetables.	Lifestyle intervention with broad health benefits beyond dementia.

Supplements: Limited Evidence

Supplement	Evidence	Recommendation
Omega-3 (DHA/EPA)	Mixed results. No benefit in established AD. Possible benefit in MCI or prevention (high-dose DHA).	Not recommended for treatment. May consider for prevention in at-risk populations (insufficient evidence).
Vitamin E	Cochrane review: No benefit. High doses (\u003e400 IU/day) may increase mortality.	Not recommended.
Ginkgo Biloba	Multiple RCTs negative (GuidAge, GEM trials). No benefit for prevention or treatment.	Not recommended.
B Vitamins (B6, B12, Folate)	Reduce homocysteine but no effect on cognition in large trials.	Treat deficiency, but supplementation above normal levels ineffective.
Vitamin D	Observational association (low D → Higher risk). RCTs pending.	Treat deficiency. Supplementation in sufficiency unclear.
Curcumin	Anti-inflammatory, antioxidant. Small trials show no benefit. Poor bioavailability.	Not recommended (insufficient evidence).

Bottom Line: No supplements proven effective for AD prevention or treatment. Focus on whole food diet (Mediterranean/MIND).

Physical Activity

Type	Recommendation	Evidence	Mechanisms
Aerobic Exercise	150 min/week moderate intensity (brisk walking, cycling, swimming). OR 75 min/week vigorous intensity.	Strong evidence. Reduces AD risk by ~30-40%. Slows decline in established AD. [16,18,23]	↑ Cerebral blood flow. ↑ BDNF (neuroplasticity). ↑ Hippocampal volume. ↓ Inflammation. ↓ Vascular risk.
Resistance Training	2-3 sessions/week.	Emerging evidence. Benefits executive function, muscle mass (prevents frailty).	↑ Muscle strength. ↑ Insulin sensitivity. ↓ Falls risk.
Combination	Aerobic + Resistance + Balance exercises.	Best evidence for multimodal exercise programmes.	Synergistic effects.

Practical Advice:

Start at any age - never too late.
Consistency more important than intensity.
Group exercise classes (social + physical benefit).
Tai Chi, yoga (balance, flexibility, falls prevention).

Cognitive Engagement and Reserve

Cognitive Reserve Hypothesis: [18]

Higher education, occupational complexity, lifelong learning, bilingualism, mentally stimulating activities → Build neural redundancy (cognitive reserve).
Reserve allows brain to compensate for pathology (tolerate more Aβ/tau before symptoms appear).
Higher reserve → Later symptom onset. BUT faster decline once symptoms emerge (steeper trajectory - less reserve left).

Activity	Evidence	Recommendation
Education	≥12 years education reduces risk by ~10-20%.	Lifelong learning. Adult education, languages, musical instruments.
Cognitively Stimulating Leisure	Reading, puzzles, board games, crosswords, learning new skills.	Regular engagement (daily). Varied activities.
Bilingualism	Bilinguals develop dementia ~4-5 years later than monolinguals.	Learn second language (benefit at any age).
Occupational Complexity	Jobs requiring high cognitive demand (management, teaching, professional roles).	Career choices. Continue mentally challenging activities in retirement.

Note: Cognitive training programmes (computerised brain training) have limited evidence for generalised cognitive benefit or dementia prevention. [18]

Cardiovascular Risk Management

"What's good for the heart is good for the brain": [16]

Risk Factor	Target	Intervention	Evidence
Hypertension	\u003c130/80 mmHg (midlife).	ACEi, ARBs, CCBs, thiazides. DASH diet. Weight loss.	Midlife hypertension → 60% ↑ AD risk. Treatment reduces risk.
Type 2 Diabetes	HbA1c \u003c7% (53 mmol/mol).	Lifestyle (diet, exercise), Metformin, SGLT2i, GLP-1 agonists.	Diabetes → 50-100% ↑ AD risk. Good glycaemic control reduces risk.
Hypercholesterolaemia	LDL \u003c3.0 mmol/L (high risk: \u003c1.8).	Statins, ezetimibe, PCSK9 inhibitors. Mediterranean diet.	Midlife high cholesterol associated with AD risk. Statin trials mixed (no clear benefit for AD prevention).
Atrial Fibrillation	Rate/rhythm control. Anticoagulation (stroke prevention).	Anticoagulants (DOACs, warfarin).	AF → ↑ Stroke → Vascular dementia. Anticoagulation reduces vascular dementia risk.
Smoking	Complete cessation.	NRT, varenicline, bupropion, counselling.	Smoking → 60% ↑ AD risk. Cessation reduces risk (benefit even if quit at 60+).

Sleep and Dementia Risk

Aspect	Evidence	Mechanism	Intervention
Sleep Duration	Both short (\u003c6h) and long (\u003e9h) sleep associated with ↑ AD risk (U-shaped).	Optimal: 7-8 hours/night.	Sleep hygiene. Treat insomnia.
Sleep Quality	Poor sleep quality, frequent awakenings → ↑ Risk.	Sleep crucial for glymphatic clearance of Aβ and tau during deep sleep. Disrupted sleep → Accumulation. [24]	Treat sleep disorders (OSA, insomnia).
Obstructive Sleep Apnoea (OSA)	OSA associated with ↑ AD risk.	Hypoxia, sleep fragmentation, impaired clearance.	CPAP therapy may reduce risk (trials ongoing). Screen for OSA (snoring, daytime sleepiness).
Circadian Rhythm	Shift work, irregular sleep-wake cycles → ↑ Risk.	Circadian disruption impairs Aβ clearance.	Regular sleep schedule. Minimise shift work. Bright light exposure (morning).

Factor	Evidence	Intervention
Social Isolation	Living alone, lack of social contact → 60% ↑ AD risk. [16]	Maintain social networks (family, friends, community). Join groups (hobbies, volunteering, religious). Combat loneliness.
Marital Status	Married/partnered → Lower risk than single/widowed/divorced.	Social support. Cognitive stimulation from interaction.
Volunteering	Regular volunteering associated with reduced risk.	Community engagement. Purpose. Social interaction.

Multidomain Interventions: FINGER Trial

FINGER (Finnish Geriatric Intervention Study): [25]

First large RCT showing multidomain intervention can reduce cognitive decline in at-risk elderly (60-77 years).
Intervention: Diet (Mediterranean/MIND), Exercise (aerobic + resistance), Cognitive training, Vascular risk management (BP, lipids, glucose), Social activities.
Results: 25% improvement in overall cognition vs control. 83% improvement in executive function. 150% improvement in processing speed.
Implication: Multidomain lifestyle intervention targeting multiple risk factors simultaneously more effective than single interventions.

Ongoing Trials: MIND-ADmini (USA), HATICE (Europe), MEDEX-UK - testing similar multidomain approaches.

Emerging Prevention Targets

Target	Rationale	Status
Amyloid Immunotherapy (Preclinical AD)	Anti-Aβ antibodies (lecanemab, donanemab) in asymptomatic amyloid-positive individuals.	Trials ongoing (AHEAD, DIAN-TU). May prevent/delay symptom onset.
GLP-1 Receptor Agonists	Diabetes drugs (semaglutide, liraglutide). Neuroprotective in animal models.	Observational data suggest ↓ dementia risk in diabetics treated with GLP-1 RAs. RCTs needed.
Anti-inflammatory Agents	NSAIDs, complement inhibitors. Target neuroinflammation.	Past trials (NSAIDs) negative. New agents (complement inhibitors) in development.
Tau Vaccines/Antibodies	Target tau aggregation/spread.	Early-phase trials.
Senolytic Drugs	Remove senescent cells (contribute to neuroinflammation).	Preclinical.

13. Advanced Diagnostics and Biomarkers

Blood-Based Biomarkers (2020-2026 Advances)

A major breakthrough in AD diagnostics: Blood tests now approaching CSF/PET accuracy for detecting AD pathology. [26]

Biomarker	Technology	Performance	Clinical Use	Availability
Plasma Aβ42/Aβ40 Ratio	Immunoassay (Simoa, immunoprecipitation-MS)	Sensitivity 80-90%, Specificity 85-90% for brain amyloidosis (vs Amyloid PET).	Screen for amyloid pathology. Predict progression MCI→AD. Monitor anti-amyloid therapy.	Research. Emerging clinical labs (LabCorp, Quest USA).
Plasma p-tau181	Simoa, immunoassay	High accuracy (AUC 0.85-0.95) for AD vs non-AD dementias. Correlates with tau PET.	Differential diagnosis (AD vs FTD/DLB). Predict progression.	Research. Becoming available clinically.
Plasma p-tau217	Simoa, immunoassay	Best-performing plasma biomarker. AUC \u003e0.95 for AD. Correlates with tau PET, cognitive decline.	Early detection (preclinical AD). High specificity.	Research. Limited availability.
Plasma p-tau231	Simoa	Very early changes (detectable in preclinical AD).	Early detection. Research.	Research only.
Plasma GFAP (Glial Fibrillary Acidic Protein)	Simoa	Elevated in AD. Reflects astrocytic activation/neurodegeneration.	Non-specific (↑ in many brain injuries). Prognostic marker.	Research.
Plasma NfL (Neurofilament Light)	Simoa	Elevated in neurodegeneration (AD, FTD, ALS, MS, stroke). Non-specific.	General neurodegeneration marker. Track progression. Differential (normal in psychiatric).	Research + Clinical labs.

Clinical Trajectory:

2020-2022: Proof-of-concept studies (academic labs, Simoa technology).
2023-2025: Large validation studies (BioFINDER-2, ADNI, multicenter cohorts). FDA Breakthrough Device Designation for plasma p-tau217 tests.
2026+: Entering clinical practice. FDA approval anticipated (some plasma Aβ tests already CE-marked in Europe). Projected to replace/reduce need for CSF and PET in many scenarios.

Advantages over CSF/PET:

Minimally invasive (blood draw vs lumbar puncture or PET scan).
Lower cost ($200-500 vs $3,000-5,000 for PET).
Scalable (can be used in primary care for screening).
Repeat measurements (monitor therapy response).

Current Limitations:

Standardisation needed (different assays, cut-offs).
Not yet routine clinical use in most countries (2026).
Interpretation challenges (what to do with asymptomatic positive?).
Ethical considerations (predictive testing, disclosure).

PET Imaging: Beyond Amyloid

Tracer	Target	Clinical Use	Availability
Amyloid PET (Florbetapir, Florbetaben, Flutemetamol)	Aβ plaques	Detect amyloid pathology. Negative scan rules out AD. Positive scan does NOT confirm AD (elderly may be amyloid+ without dementia).	FDA/EMA approved. Specialist centres. Expensive. Limited reimbursement.
Tau PET (Flortaucipir, MK-6240, PI-2620, RO948)	Neurofibrillary tangles	Maps tau distribution (correlates better with cognition than amyloid PET). Track disease stage (Braak). Monitor anti-tau therapies.	Research (some FDA approval). Becoming available in specialist centres. 2nd-generation tracers better (less off-target binding).
Neuroinflammation PET (TSPO ligands, e.g., PBR28)	Activated microglia	Detect neuroinflammation. Research tool.	Research only.
Synaptic Density PET (SV2A tracers, e.g., UCB-J)	Synaptic vesicle protein SV2A	Quantify synaptic loss (earliest change in AD). Correlates with cognition.	Research only. Promising biomarker.

A/T/N Framework (NIA-AA 2018): [5]

A: Amyloid (Aβ PET+, CSF Aβ42 low, plasma Aβ42/40 low)
T: Tau (Tau PET+, CSF p-tau high, plasma p-tau high)
N: Neurodegeneration (FDG-PET hypometabolism, MRI atrophy, CSF t-tau high, plasma NfL high)

Biological Definition of AD: A+T+ (regardless of symptoms).

Preclinical AD: A+T+N± without cognitive symptoms.
Prodromal AD (MCI due to AD): A+T+N+ with MCI.
AD Dementia: A+T+N+ with dementia.

Digital Biomarkers and Wearables

Emerging technologies using digital phenotyping for early AD detection: [27]

Technology	Measure	Evidence	Status
Smartphone Speech Analysis	Acoustic features (pauses, articulation, semantic content).	AI models detect MCI/AD from brief speech samples (AUC 0.80-0.90).	Research. Apps in development.
Eye Tracking	Saccades, visual attention, pupillary response.	Abnormalities in AD (impaired visual search, attentional deficits).	Research.
Actigraphy (Wearables)	Sleep-wake patterns, physical activity, circadian rhythm.	Sleep fragmentation, reduced activity predict AD.	Consumer devices (Fitbit, Apple Watch). Research using for AD prediction.
Driving Monitoring	GPS tracking, braking patterns, navigation errors.	Driving performance deteriorates early in MCI/AD.	Research. In-car sensors.
Smart Home Sensors	Activity patterns (cooking, toileting, sleep), social interaction.	Detect functional decline (IADLs) objectively.	Research. Pilot studies.
Typing/Mouse Dynamics	Keystroke patterns, mouse movement.	Slowed, erratic patterns in AD.	Research (easy to implement).

Future Vision: Continuous monitoring via smartphones/wearables → AI algorithms detect subtle changes → Early warning system for MCI/AD. Challenges: Privacy, data security, validation, regulatory approval.

Retinal Imaging

Retina as "window to the brain": [28]

Technology	Finding in AD	Status
Optical Coherence Tomography (OCT)	Retinal nerve fibre layer (RNFL) thinning. Ganglion cell layer loss.	Observational studies show association. Not diagnostic (overlap with normal aging, glaucoma).
Hyperspectral Retinal Imaging	Detect Aβ deposits in retina.	Experimental. Curcumin eye drops + imaging. Early-stage research.
Retinal Vasculature	Vascular changes (narrowing, tortuosity).	Associated with AD risk. Non-specific.

Current View: Promising research area. Not yet clinically useful for AD diagnosis. May become screening tool if validated.

14. Special Populations and Atypical Presentations

Early-Onset Alzheimer's Disease (EOAD, \u003c65 years)

Aspect	EOAD	LOAD (\u003e65 years)
Prevalence	5-10% of all AD cases.	90-95% of AD cases.
Age of Onset	\u003c65 years (some as young as 30s with familial mutations).	\u003e65 years (risk increases exponentially with age).
Genetics	Higher genetic contribution. ~13% autosomal dominant (APP, PSEN1, PSEN2). Higher APOE ε4 prevalence.	Mostly sporadic. APOE ε4 major risk factor.
Clinical Features	More atypical presentations: Posterior Cortical Atrophy (PCA), Logopenic Primary Progressive Aphasia (lvPPA), frontal-executive variant.	Classic amnestic presentation (memory-first).
Progression	Faster progression. More aggressive. Median survival ~6-8 years from symptom onset.	Slower. Median survival ~8-10 years.
Comorbidities	Fewer age-related comorbidities.	Multiple comorbidities (vascular, metabolic).
Diagnosis Delay	Often delayed (not suspected in younger adults - mistaken for stress, depression, burnout).	More readily recognised.
Impact	Devastating: Working age, family responsibilities (young children), financial (loss of income, mortgages), social isolation.	Retired, different care challenges.
Genetic Counselling	Recommended if family history (autosomal dominant pattern). Predictive testing available (ethical considerations).	Not routine.

Atypical AD Variants (Common in EOAD): [29]

Posterior Cortical Atrophy (PCA)

Feature	Details
Primary Deficit	Visuospatial and visuoperceptual dysfunction (not memory).
Symptoms	Difficulty reading (word-by-word), judging distances, recognising objects/faces, navigating, dressing (spatial components). Balint syndrome (simultanagnosia, optic ataxia, oculomotor apraxia). Gerstmann syndrome (agraphia, acalculia, finger agnosia, left-right disorientation).
Memory	Relatively preserved early (distinguishes from typical AD).
Imaging	Biparietal and occipital atrophy (posterior predominant). Sparing of hippocampus early.
Pathology	Most cases (70-80%) are AD pathology (Aβ + tau). Minority: DLB, CBD.
Age	Younger onset (50s-60s).

Logopenic Variant Primary Progressive Aphasia (lvPPA)

Feature	Details
Primary Deficit	Language - word-finding pauses, impaired sentence repetition, phonological errors.
Symptoms	Slow, halting speech. Difficulty retrieving words (anomia). Impaired repetition of long sentences. Comprehension relatively preserved (vs semantic variant PPA). Grammar preserved (vs nonfluent/agrammatic variant).
Memory	Impaired (AD pathology).
Imaging	Left temporoparietal atrophy.
Pathology	Most are AD (Aβ + tau). Unlike other PPA variants (semantic = FTD, nonfluent = FTD/CBD).
Age	Older than other PPAs (60s-70s).

Frontal/Executive Variant AD

Feature	Details
Primary Deficit	Executive dysfunction (planning, judgment, organisation). Behavioural changes.
Symptoms	Similar to behavioural variant FTD (apathy, disinhibition, poor judgment). Memory may be relatively spared early.
Imaging	Frontal atrophy (unusual for AD). May also have hippocampal involvement.
Pathology	AD (Aβ + tau). Difficult to differentiate from FTD clinically. Biomarkers essential.

Diagnostic Approach for EOAD:

Comprehensive neuropsychological testing (identify atypical patterns).
MRI: Look for atypical atrophy patterns.
Biomarkers: Amyloid PET or CSF essential to differentiate AD from FTD/other dementias (clinical overlap).
Genetic testing: Consider if strong family history (APP, PSEN1, PSEN2 sequencing). APOE genotyping (research/some clinical settings).
Functional assessment: Work impact, driving, childcare responsibilities.

Alzheimer's Disease in Down Syndrome

Aspect	Details
Prevalence	Near-universal by age 40. 50-70% have dementia by age 60. [15]
Mechanism	APP gene on Chromosome 21 → Trisomy 21 = Triple gene dosage → Lifelong Aβ overproduction → Early plaque deposition (detectable by age 12).
Age of Onset	Dementia typically develops in 50s-60s (earlier than general population). Some as young as 40s.
Clinical Features	Superimposed cognitive decline on baseline intellectual disability. Loss of previously acquired skills (ADLs, language, social). Behavioural changes (apathy, depression, aggression). Seizures (10-40%).
Diagnosis Challenges	Difficult: Baseline cognitive impairment makes decline harder to detect. Need informant history (carers). Baseline testing recommended at age 30 (then monitor for decline).
Investigations	MRI: Hippocampal atrophy (earlier than general population). Biomarkers: Amyloid PET, CSF (rarely done - consent issues).
Management	AChEIs (donepezil, rivastigmine) - some evidence of benefit in Down Syndrome with AD. Memantine. Non-pharm (maintain routines, activities). Carer support.
Prognosis	Median survival ~5-6 years from dementia diagnosis (shorter than typical AD).

Clinical Implications:

Screen for AD from age 30 in Down Syndrome (baseline cognitive assessment).
Monitor for decline (annual reviews).
Educate carers about AD risk.
Trials ongoing for prevention in Down Syndrome (anti-amyloid antibodies).

Alzheimer's Disease in Women vs Men

Sex Differences: [12]

Aspect	Women	Men
Prevalence	Higher (1.6:1 ratio). ~2/3 of AD patients are women.	Lower.
Longevity Contribution	Partly explained by longer lifespan (women live longer, more reach high-risk ages). BUT sex-specific biological differences also contribute.	Shorter lifespan.
APOE ε4 Effect	Stronger effect of APOE ε4 in women (especially ε4 homozygotes). Earlier onset, faster decline in female ε4 carriers.	Weaker effect.
Hormones	Menopause → Loss of estrogen (neuroprotective) → ↑ Risk? Hormone Replacement Therapy (HRT) trials (WHI-MS) showed no benefit (started late - critical window hypothesis).	Testosterone decline with age (less studied).
Brain Reserve	Some studies suggest women compensate better initially (verbal memory strengths) → Later symptom detection → More advanced pathology at diagnosis.	Men may show symptoms earlier relative to pathology.
Pathology	More tau pathology for same level of amyloid (some studies).	Less tau for equivalent amyloid.
Progression	Slower progression once diagnosed (longer survival).	Faster progression, shorter survival.
BPSD	Higher rates of depression, anxiety.	Higher rates of aggression, disinhibition.
Caregiving Burden	Women more likely to be carers for spouses/relatives with AD (gendered caregiving roles). Higher carer burden.	More likely to receive care from female relatives.

Research Gaps: Historically, women underrepresented in AD clinical trials. Sex as biological variable now mandated in NIH-funded research.

Alzheimer's Disease and Comorbid Psychiatric Illness

Depression and AD

Aspect	Details
Relationship	Bidirectional: Depression is risk factor for AD (60-90% ↑ risk). [16] \u003cbr\u003e Depression also prodrome of AD (early symptom before cognitive impairment). \u003cbr\u003e Depression comorbid in 40-50% of established AD.
Mechanisms	Shared pathways: Chronic stress → ↑ Cortisol → Hippocampal atrophy. Inflammation. Vascular damage. Reduced BDNF. Tau pathology in depression?
Clinical Challenge	Pseudodementia (Depression masquerading as dementia): Poor effort on testing, "don't know" answers, subjective \u003e\u003e objective impairment, reversible with antidepressants. \u003cbr\u003e OR True comorbidity (AD + Depression): Both present. Harder to treat.
Management	SSRIs (citalopram, sertraline - first-line). Avoid TCAs (anticholinergic → worsen cognition). Psychotherapy (CBT - adapted for dementia). Treat underlying AD.
Prevention?	Treating midlife depression may reduce later AD risk (epidemiological data, RCTs needed).

Psychosis in AD

Feature	Details
Prevalence	30-40% experience delusions. 10-25% experience hallucinations (less common than DLB).
Common Delusions	Persecutory ("Someone is stealing from me", "Spouse is unfaithful"). Misidentification (Capgras - familiar person replaced by imposter).
Hallucinations	Visual (less vivid/frequent than DLB). Auditory (rarer).
Timing	Usually moderate-severe stage.
Management	Non-pharmacological first: Reassurance, redirection, environmental modification, treat underlying causes (pain, infection, constipation). \u003cbr\u003e Antipsychotics (last resort): Risperidone 0.25-1mg (short-term, licensed for severe aggression in AD). BLACK BOX WARNING: ↑ Stroke risk, ↑ Mortality in dementia. Use lowest dose, shortest duration. Review every 6 weeks.

15. Clinical Cases for MRCP/FRACP Preparation

Case 1: Classic Amnestic Alzheimer's Disease

Vignette: A 72-year-old retired teacher is brought to your clinic by her daughter, who reports progressive memory problems over 2 years. The patient repeatedly asks the same questions, forgets conversations from the same day, and recently got lost driving to a familiar location. She has missed several medical appointments and struggles to manage her medications. She denies any problems and says her daughter is "overreacting". She lives alone. Past medical history: Hypertension (well-controlled on amlodipine), type 2 diabetes (metformin). No family history of dementia.

Examination: Alert, cooperative. MMSE: 22/30 (lost points on orientation to time, recall 0/3 words, unable to copy pentagons). Neurological examination otherwise normal. Gait normal.

Questions:

What is the most likely diagnosis?
What investigations would you arrange?
What is the significance of her lack of insight?
How would you manage this patient?

Model Answer:

Most likely diagnosis: Alzheimer's Disease (Mild stage).
- Gradual onset (2 years), progressive course.
- Prominent episodic memory loss (recent memory - repetitive questioning, forgets conversations).
- Impaired IADL (driving, medication management, appointments).
- Anosognosia (lack of insight - common in AD).
- MMSE 22/30 (mild dementia range).
- Age \u003e65 (typical LOAD).
- No focal neurological signs (excludes stroke/tumour).
Investigations:
- Bloods (exclude reversible causes): FBC, U\u0026E, LFT, TFT, B12, folate, glucose/HbA1c, calcium, ESR/CRP.
- MRI Brain (preferred) or CT: Assess for hippocampal/medial temporal lobe atrophy (supports AD). Exclude vascular lesions, subdural, tumour.
- Cognitive assessment: More detailed than MMSE - ACE-III or MoCA (more sensitive). Formal neuropsychological testing if available.
- Collateral history: Detailed from daughter (functional impact, timeline, BPSD).
- Consider: Amyloid PET or CSF biomarkers if atypical features or diagnostic uncertainty (not routine in classic presentation).
Significance of lack of insight (Anosognosia):
- Common in AD (frontal lobe involvement → impaired self-monitoring).
- Diagnostic clue: Supports dementia (vs depression where insight usually preserved, patients complain of memory).
- Management implications: Patient may resist help, unsafe decisions (driving, living alone), refuse medications. May lack capacity for complex decisions. Increased carer burden.
Management:
- Pharmacological:
  - Start Acetylcholinesterase Inhibitor: Donepezil 5mg OD (increase to 10mg after 4-6 weeks if tolerated). Alternatives: Rivastigmine patch, Galantamine.
  - Monitor response at 3-6 months (cognition, function, BPSD).
- Non-pharmacological:
  - Cognitive Stimulation Therapy (CST) - group-based structured activities.
  - Physical activity (walking programme).
  - Encourage social engagement.
  - Occupational therapy: Home safety assessment, ADL aids.
- Driving: Inform DVLA (legal requirement). Likely will need to stop driving (navigation deficits, got lost).
- Safety: Living alone may become unsafe. Consider:
  - Daily carer visits.
  - Medication administration aids (dosette box, carer-supervised).
  - Falls risk assessment.
  - Consider future care needs (may need residential care as progresses).
- Legal/Advance Care Planning:
  - Lasting Power of Attorney (LPA) - Health/Welfare + Property/Financial (while still has capacity).
  - Advance Decision to Refuse Treatment (ADRT).
  - Discuss future wishes (care home, resuscitation).
- Carer Support:
  - Psychoeducation for daughter (disease course, management).
  - Signpost to Alzheimer's Society, local support groups.
  - Respite care options.
  - Carer's Allowance (financial support).
- Follow-up: Regular reviews (3-6 monthly). Monitor progression, medication tolerance, BPSD, carer wellbeing.

Examination Pearls:

Always ask about driving (legal and safety issue).
Collateral history essential in dementia (patient may not report deficits).
Differentiate IADL (finances, driving, medications - impaired in MCI/mild dementia) vs ADL (dressing, bathing, eating - impaired in moderate-severe).
Capacity assessment: Presume capacity unless proven otherwise. Decision-specific and time-specific. Use Mental Capacity Act principles.

Case 2: Differential Diagnosis - AD vs DLB

Vignette: An 78-year-old man presents with 18-month history of cognitive decline. His wife reports he has "good days and bad days"

some days he is relatively clear, other days very confused. He has seen "small people" in the house on multiple occasions (she has not seen them). He has become slower in his movements and has fallen twice. MMSE: 18/30. Examination: Bradykinesia, mild rigidity (arms \u003e legs), shuffling gait. No tremor. Postural instability. MRI brain: Mild generalised atrophy, no focal lesions.

Questions:

What are the two most likely differential diagnoses?
What clinical features help differentiate them?
What additional test would you request to aid diagnosis?
What medication should be avoided and why?

Model Answer:

Top Two Differentials:
- Dementia with Lewy Bodies (DLB) - Most likely.
- Alzheimer's Disease with incidental Parkinsonism (less likely given constellation).

Clinical Features Favouring DLB (vs AD):

Feature	DLB (This Case)	Alzheimer's Disease
Fluctuating Cognition	✅ "Good days, bad days" - Core feature of DLB.	Stable decline (no day-to-day fluctuation).
Visual Hallucinations	✅ "Small people" - Recurrent, detailed visual hallucinations. Core feature.	Uncommon (10-25%). Less vivid.
Parkinsonism	✅ Bradykinesia, rigidity, shuffling gait. Occurs early (within 1 year of cognitive symptoms). Core feature.	None until very late stage (if at all).
Falls	✅ Common (parkinsonism, postural instability, autonomic dysfunction).	Later in disease.
Memory Impairment	Present but fluctuates. Attention/visuospatial worse.	Prominent, early, progressive memory loss.
MRI	Relative preservation of medial temporal lobes (vs AD).	Hippocampal atrophy characteristic.
REM Sleep Behaviour Disorder	Common (not mentioned here but ask about - acting out dreams, shouting in sleep).	Rare.
Neuroleptic Sensitivity	Severe reactions to antipsychotics (rigidity, sedation, NMS-like).	Less sensitive.

Diagnosis: DLB (3/4 core features present: Fluctuating cognition + Visual hallucinations + Parkinsonism).

Additional Investigation: DaTscan (Dopamine Transporter SPECT Imaging):
- DLB: Abnormal - Reduced striatal dopamine transporter uptake ("comma" or "full stop" sign).
- AD: Normal - Preserved striatal uptake.
- Utility: Differentiates DLB/PDD from AD and other dementias. High sensitivity/specificity.
Medication to AVOID: Antipsychotics (e.g., haloperidol, olanzapine, risperidone):
- Why: DLB patients have severe neuroleptic sensitivity → Worsening parkinsonism, rigidity, sedation, confusion, NMS-like reactions, ↑ mortality.
- If hallucinations need treatment: Use non-pharmacological approaches first. If essential: Quetiapine (lowest D2 blockade - but still risky). AChEIs (rivastigmine) may help hallucinations in DLB.

Key Learning Points:

DLB core features (remember "FVPR"): Fluctuating cognition, Visual hallucinations, Parkinsonism, REM sleep behaviour disorder.
DaTscan useful in DLB vs AD differentiation.
Never give typical antipsychotics in DLB (severe sensitivity).
AChEIs (rivastigmine) are treatment of choice in DLB (licensed for DLB, helps cognition and BPSD including hallucinations).

Case 3: Young-Onset Dementia

Vignette: A 56-year-old accountant is referred by his GP for memory problems. His wife reports a 3-year history of decline: difficulty with calculations at work (previously excellent with numbers), trouble reading (skips lines, loses place), bumps into doorframes, difficulty judging distances when parking the car. He has no trouble recognising people or remembering conversations. MMSE: 26/30 (lost points on copying pentagons, serial 7s). Examination: Cannot copy overlapping pentagons. Optic ataxia (difficulty reaching for objects under visual guidance). Simultanagnosia (can only see one object at a time in complex scene). Eye movements normal. No parkinsonism.

Questions:

What is the most likely diagnosis?
Which brain regions are affected?
What imaging findings would you expect?
What is the likely underlying pathology?

Model Answer:

Most Likely Diagnosis: Posterior Cortical Atrophy (PCA) - Atypical Alzheimer's Disease.
Brain Regions Affected: Biparietal and occipital cortices (posterior predominant).
- Parietal lobe dysfunction: Visuospatial deficits (judging distances, navigation), acalculia (calculation difficulties), constructional apraxia (cannot copy figures), optic ataxia.
- Occipital lobe involvement: Visual processing deficits, simultanagnosia.
- Hippocampus relatively spared (memory preserved - distinguishes from typical AD).
Imaging Findings: MRI Brain:
- Biparietal atrophy (bilateral, symmetric).
- Occipital atrophy.
- Relative sparing of medial temporal lobes (hippocampus) early in disease.
- Later: Spread to temporal/frontal regions.
- FDG-PET: Hypometabolism in parieto-occipital regions.
Underlying Pathology:
- 70-80% are AD pathology (Aβ plaques + tau tangles) - same as typical AD but posterior distribution.
- Minority: Dementia with Lewy Bodies, Corticobasal Degeneration, Prion disease (very rare).
- Confirm with biomarkers: Amyloid PET (positive in AD-PCA) or CSF (low Aβ42, high tau/p-tau).

Management:

Acetylcholinesterase Inhibitors (donepezil, rivastigmine) - same as typical AD.
Occupational therapy: Visual aids, environmental modifications (reduce clutter, high-contrast labels, simplify visual environment).
Genetic testing: Consider in early-onset (\u003c65) if family history (APP, PSEN1, PSEN2).
Driving: Must stop (severe visuospatial deficits - unsafe).
Supportive: PCA Support Group (specific for this variant). Adjust expectations (reading, driving may be lost early, but memory/language preserved longer).

Examination Pearls:

Balint Syndrome triad (in PCA): Simultanagnosia (cannot perceive multiple objects), Optic ataxia (misreaching under visual guidance), Oculomotor apraxia (difficulty initiating voluntary saccades).
Gerstmann Syndrome (dominant parietal): Agraphia, Acalculia, Finger agnosia, Left-right disorientation.
PCA patients often present to ophthalmology first ("I can't see") - eye exam normal (problem is cortical, not ocular).
Memory preserved early differentiates from typical AD.

16. International Perspectives and Global Health

Alzheimer's Disease Burden by Region

Region	Estimated Prevalence (2020)	Projected (2050)	Key Challenges
Asia-Pacific	~28 million	~78 million (largest increase)	Rapidly aging populations (China, India, Japan). Limited healthcare infrastructure in LMICs. Stigma. Low diagnosis rates (\u003c30% diagnosed). [11]
Europe	~10 million	~19 million	Aging populations. High healthcare costs. Variability in dementia care quality across countries.
Americas	~11 million	~29 million	USA: High costs ($360 billion/year in 2024). Latin America: Underdiagnosis, limited access to specialists.
Africa	~4 million	~16 million (fastest % increase)	Youngest region demographically but aging rapidly. Extreme shortage of dementia specialists. Stigma ("madness", witchcraft). Limited data. [11]
Middle East	~2 million	~7 million	Cultural factors (family care predominates). Limited formal dementia services.

Low- and Middle-Income Countries (LMICs)

Challenges: [11]

58% of dementia patients live in LMICs (2020) → 68% by 2050.
Low diagnosis rates: \u003c10% diagnosed in many LMICs (vs 40-50% in high-income countries).
Lack of specialists: Many countries have \u003c1 dementia specialist per million population.
No dementia plans: Most LMICs lack national dementia strategies.
Stigma: Dementia seen as "madness", "curse", "normal aging" → Families hide affected members.
Limited medications: AChEIs/memantine not available or unaffordable.
Informal care: 90%+ care by family (often women) with no support.

Opportunities:

WHO Global Action Plan on Dementia (2017-2025): Calls for national dementia plans, improved diagnosis, care, prevention. [30]
Low-cost interventions: Cognitive stimulation, caregiver training (effective, affordable).
Task-shifting: Train primary care workers, community health workers in dementia care (specialist shortages).
Stigma reduction campaigns: Education, media.

Cultural Considerations in Dementia Care

Culture	Care Preferences	Challenges
Asian (China, India, Japan, Korea)	Filial piety - strong expectation that children care for elderly parents at home. Institutional care seen as "abandoning" parents (shameful).	Family burden high. Women bear most care. Reluctance to seek outside help.
African	Extended family care. Community-based support. Stigma (witchcraft, curses).	Lack of formal services. Migration (young generation to cities → Elderly left in villages without carers).
Middle Eastern	Family care (often daughters/daughters-in-law). Gender segregation affects care delivery (male doctors examining women).	Women's caregiving burden. Limited respite.
Mediterranean (Southern Europe, Latin America)	Family-centred care. Low nursing home use.	High family burden. Care often falls to female relatives. Economic crises affect ability to provide care.
Western (Northern Europe, North America)	Mix of family and institutional care. Increasing acceptance of care homes, assisted living.	High costs. Geographic dispersal of families (children live far from aging parents). "Sandwich generation" (caring for parents + children).

Clinical Implications:

Assess cultural background and care preferences.
Involve family in decision-making (varying degrees of patient autonomy across cultures).
Be sensitive to stigma (use language carefully - "memory problems" may be more acceptable than "dementia" in some cultures).
Adapt cognitive tests for language, education, cultural norms (e.g., MMSE "Serial 7s" or "WORLD backwards"
literacy-dependent).

17. Recent Advances and Future Directions (2023-2026)

Breakthrough Therapies

Anti-Amyloid Monoclonal Antibodies: Real-World Implementation [9,10]

Lecanemab (Leqembi) - FDA approved Jan 2023, MHRA (UK) approved Aug 2024:

Mechanism: Humanised IgG1 monoclonal antibody targeting soluble Aβ protofibrils (toxic oligomers).
Dosing: 10 mg/kg IV infusion every 2 weeks (Q2W).
Efficacy (CLARITY-AD trial, N=1795): 27% slower decline on CDR-SB (Clinical Dementia Rating Sum of Boxes) vs placebo over 18 months. Absolute difference: 0.45 points. Statistically significant (p\u003c0.001) but modest clinical meaningfulness debated.
Safety: ARIA-E (edema) 12.6%, ARIA-H (hemorrhage) 17.3%. 3 deaths potentially related to ARIA (on anticoagulation).
Eligibility: Early AD (MCI due to AD or mild AD dementia), confirmed brain amyloidosis (PET or CSF), MMSE \u003e20 (approximately), able to undergo MRI monitoring.
Monitoring: MRI at baseline, before 5th, 7th, 14th infusions (months ~3, 4, 7), then annually. More frequent if ARIA detected.
APOE ε4 risk: Homozygotes (ε4/ε4) have ~4x higher ARIA risk than non-carriers. More intensive MRI monitoring required.
Cost: ~$26,500/year (USA). NICE (UK) decision (2024): Not recommended for routine NHS use (cost-effectiveness threshold not met - ICER ~£130,000/QALY, vs £20,000-30,000 threshold). Available via private payment or special access schemes.

Donanemab (Kisunla) - FDA approved July 2024:

Mechanism: Humanised IgG1 targeting N-terminal pyroglutamate Aβ plaques (more mature plaques).
Dosing: 700 mg (≤85 kg) or 1050 mg (\u003e85 kg) IV infusion every 4 weeks (Q4W).
Efficacy (TRAILBLAZER-ALZ 2, N=1736): 22-35% slower decline on iADRS (integrated AD Rating Scale) vs placebo over 18 months in early AD. Greater benefit in low/medium tau subgroup (35% slowing) vs high tau (modest benefit).
Innovative aspect: Treatment until amyloid clearance, then stop (tau-guided stopping rule). ~50% reached amyloid clearance by 12 months → Discontinued. Reduces infusion burden, ARIA risk, cost.
Safety: ARIA-E 24%, ARIA-H 19.7%. 3 deaths related to ARIA.
Regulatory: FDA approved. NICE: Under review (2025 decision expected).

Practical Implementation Challenges:

Amyloid confirmation required: Need Amyloid PET (~$5,000, limited availability, not all insurers cover) OR CSF biomarkers (lumbar puncture - patient reluctance) OR blood-based biomarkers (emerging, not yet standard). ~30% of clinically diagnosed AD are amyloid-negative (would not benefit).
Infusion infrastructure: Requires IV infusion centres (Q2W or Q4W). Capacity constraints. Patient travel burden.
MRI monitoring: Frequent MRIs (detect ARIA). Costly. MRI contraindications (pacemakers, claustrophobia, renal impairment if contrast needed).
APOE ε4 genotyping: Needed for risk stratification (homozygotes have high ARIA risk). Ethical issues (genetic information disclosure, insurance discrimination concerns).
Cost and access: Very expensive. Most countries (except USA) have not approved for public funding (cost-effectiveness). Equity concerns: Only wealthy patients can access (exacerbates health disparities).
Modest benefit: Slows decline by ~5-6 months over 18 months. Does NOT stop progression or reverse disease. Unclear if clinically meaningful to patients/families.

Who Benefits Most?: [9,10]

Early disease (MCI due to AD, mild AD). Moderate-severe AD excluded from trials.
Confirmed amyloid pathology (biomarker+).
Low-medium tau burden (donanemab data - high tau patients benefited less).
APOE ε4 non-carriers or heterozygotes (lower ARIA risk).
Patients willing to accept risks (ARIA, infusions, monitoring burden).

2026 Perspective: Limited uptake in real-world practice due to cost, access barriers, modest benefit, regulatory restrictions (UK NICE rejection). Primarily used in USA (Medicare covers if amyloid-confirmed), research settings, clinical trials. Future: Awaiting longer-term data (does slowing persist beyond 18 months?), combination therapies (anti-amyloid + anti-tau), earlier intervention (preclinical AD prevention trials ongoing).

Other Disease-Modifying Approaches in Development

Approach	Examples	Mechanism	Status
Anti-Tau Therapies	Semorinemab, Tilavonemab, Zagotenemab (monoclonal antibodies). LMTM/TRx0237 (tau aggregation inhibitor).	Block tau spread, aggregation. Clear extracellular tau.	Phase 2/3 trials. Most negative so far. New generation being tested.
Combination Therapy	Anti-Aβ + Anti-tau.	Target both pathologies simultaneously.	Trials planned (2025-2027).
BACE Inhibitors	Verubecestat, Atabecestat, Elenbecestat.	Inhibit β-secretase → ↓ Aβ production.	All failed Phase 3 (cognitive worsening, liver toxicity, no benefit). Approach largely abandoned.
Gamma-Secretase Modulators	-	Shift γ-secretase cleavage → ↓ Aβ42, ↑ shorter (less toxic) Aβ species.	Early-phase.
Anti-Inflammatory	Complement inhibitors (ANX005, Danicopan). NLRP3 inhibitors. Anti-IL1β.	Block neuroinflammation (complement, inflammasome).	Phase 2 trials ongoing.
Neuroprotection	GLP-1 receptor agonists (Semaglutide, Liraglutide).	↑ Insulin signalling, neuroprotection, ↓ inflammation.	Repurposing diabetes drugs. Phase 3 trial (EVOKE - semaglutide in early AD) results 2025.
Synaptic Protection	Saracatinib (Fyn kinase inhibitor).	Prevent synaptic loss (Fyn kinase mediates Aβ synaptic toxicity).	Phase 2.
Gene Therapy	AAV-delivered APOE2 (replace ε4 with protective ε2).	Genetic modification.	Preclinical. Extreme future.
Lifestyle Interventions	Multidomain (FINGER-style trials): Diet, exercise, cognitive training, vascular risk mgmt.	Address multiple modifiable risk factors.	Multiple Phase 3 trials ongoing worldwide (US-POINTER, MIND-ADmini, PRODEMOS, etc). Results 2025-2027. [25]

Blood Biomarker Revolution

Game-Changer for AD Diagnostics: [26]

2024-2026: Plasma p-tau217 and Aβ42/40 ratio tests achieving 85-95% accuracy for detecting AD pathology (approaching PET/CSF gold standards).
FDA Breakthrough Device Designation granted to C2N Diagnostics (PrecivityAD2™ blood test - plasma Aβ42/40 + APOE) and ALZpath (plasma p-tau217) in 2023-2024.
Clinical deployment beginning: LabCorp, Quest Diagnostics (USA) offering plasma Aβ tests clinically (2024-2025). UK NHS pilot studies using plasma biomarkers in memory clinics (2025-2026).

Future Vision (2026-2030):

Primary care screening: GP blood test → If positive + symptoms → Refer to specialist.
Clinical trial recruitment: Screen with blood test (replace expensive PET screening).
Monitor therapy: Serial blood biomarkers track treatment response (donanemab/lecanemab - does Aβ clearance on PET correlate with p-tau decline in blood?).
Population screening?: Controversial - screen asymptomatic 60-year-olds → Predict risk → Offer prevention trials? Ethical minefield (no proven prevention yet, psychological harm, insurance/employment discrimination).

Remaining Challenges:

Standardisation: Multiple assay platforms (Simoa, Lumipulse, MSD), different antibodies, different cut-offs → Need for harmonisation.
Interpretation: What does "abnormal" plasma biomarker in asymptomatic person mean? When to act?
Regulation: Path to FDA/MHRA approval as diagnostic tests (not just research use).
Reimbursement: Will insurance/NHS pay?

Artificial Intelligence and Machine Learning

AI Applications in AD: [27]

Application	Technology	Status
Early Detection	Machine learning models combining multimodal data (MRI, PET, cognitive tests, genetics, blood biomarkers) → Predict MCI→AD conversion with ~85-90% accuracy 2-3 years before clinical diagnosis.	Research. FDA cleared BrainSee (Darmiyan) - AI MRI analysis for hippocampal volume (2023).
Automated Imaging Analysis	Deep learning algorithms segment hippocampus, quantify atrophy, detect amyloid/tau PET patterns. Faster, more objective than visual reads.	Clinical deployment starting (FDA-approved algorithms for MRI volumetry).
Digital Phenotyping	Smartphone apps, wearables, smart home sensors → Passive monitoring of cognition, speech, activity, sleep → AI detects subtle changes predicting decline.	Research. Consumer apps emerging (LVL Health, Cogstate Brief Battery). Not yet validated for diagnosis.
Drug Discovery	AI-designed molecules targeting Aβ, tau, neuroinflammation. Identify new targets from large datasets (genomics, proteomics).	Pharma investment. Verge Genomics, BenevolentAI using AI for AD drug discovery. Early stage.
Risk Prediction	Polygenic risk scores (PRS) combining 75+ genetic loci + lifestyle factors → Personalize risk estimates.	Research. Not clinically actionable yet (no proven prevention).
Clinical Trial Optimization	AI identifies optimal trial participants (biomarker profiles most likely to show drug effect). Predicts dropouts. Optimizes endpoints.	Pharma using extensively. Improved trial efficiency.

Caution: AI tools not yet ready for solo clinical decision-making. Risk of algorithmic bias (trained on non-diverse populations → May misdiagnose minorities). Black box problem (can't explain why AI made prediction). Regulatory oversight needed.

18. Medicolegal and Ethical Issues

Mental Capacity Act 2005 (England \u0026 Wales): [31]

Principles:

Presume capacity unless proven otherwise.
Support person to make own decisions (provide information, time, communication aids).
Unwise decisions ≠ lack of capacity (right to make "bad" choices).
Decisions must be in person's best interests if they lack capacity.
Least restrictive option.

Assessing Capacity (4-stage test):

Understand information relevant to decision.
Retain information (at least temporarily).
Weigh information (consider pros/cons).
Communicate decision (verbally, writing, sign language, behaviour).

If lacks capacity → Best Interests Decision (consider: person's past/present wishes, beliefs, values; consult family/carers; least restrictive).

Common Scenarios in AD:

Decision	Capacity Issues
Medications	Mild AD: Usually has capacity to consent. Moderate-Severe: Often lacks capacity → Best interests (doctor + family decide).
Driving	DVLA decides fitness to drive, not patient. Doctor advises DVLA. Patient may lack insight (anosognosia) → Continue driving despite being unsafe. Doctor may need to breach confidentiality and inform DVLA if patient refuses and poses serious risk.
LPA (Lasting Power of Attorney)	Must have capacity at time of making LPA. Mild AD: Act quickly while capacity retained. Moderate+: Too late (cannot make LPA).
ADRT (Advance Decision to Refuse Treatment)	Must have capacity when making ADRT. Specific treatments (e.g., CPR, antibiotics, tube feeding). Legally binding if valid and applicable.
Care Home Placement	If lacks capacity and refuses → Deprivation of Liberty Safeguards (DoLS) may be needed (if care home placement constitutes deprivation of liberty).
Research Participation	Can participate if has capacity to consent. If lacks capacity → Consultee (family member) can advise if person would have wanted to participate. Mental Capacity Act allows research on incapacitated adults if certain criteria met.

Driving and Dementia

UK Law (DVLA): [32]

Must notify DVLA if diagnosed with dementia (legal requirement).
Failure to notify = Criminal offence (£1,000 fine). Insurance invalid.
Doctor's duty: Advise patient to notify DVLA. Document advice in notes. If patient refuses and doctor judges serious risk to public → Doctor may breach confidentiality and inform DVLA directly (GMC guidance permits).

DVLA Assessment:

Mild dementia: May retain licence with annual review (depends on cognitive testing, on-road assessment).
Moderate-severe dementia: Licence revoked.
HGV/Bus licence: More stringent (usually revoked at dementia diagnosis).

Practical Advice:

Discuss driving early in diagnosis.
Offer on-road assessment (occupational therapist driving assessment).
Arrange alternative transport (family, taxis, public transport, community transport schemes).
Be sensitive (driving = independence, identity for many - losing licence is significant loss).

Restraint and Deprivation of Liberty

Deprivation of Liberty Safeguards (DoLS) (England \u0026 Wales): [33]

When needed: Person in care home or hospital lacks capacity to consent to placement AND placement constitutes deprivation of liberty (continuous supervision, not free to leave, unable to consent).
Dementia patients in care homes: Often meet criteria → DoLS application needed (care home manager applies to Local Authority).
Purpose: Safeguard against unlawful detention. Independent assessor reviews. Authorisation (usually 12 months). Right to appeal.

Physical Restraint:

Last resort. Only if necessary to prevent harm. Least restrictive option. Proportionate.
Document clearly. Review frequently. Consider alternatives (environmental modification, distraction, medication review).

Chemical Restraint (Sedative medications for behaviour control):

Controversial. Only if severe BPSD causing risk to patient/others AND non-pharm failed.
Antipsychotics = Increased stroke/death risk in dementia (Black Box Warning). Use sparingly, lowest dose, shortest duration.
Must be in best interests. Document decision-making. Family involvement.

End-of-Life Decisions

DNAR (Do Not Attempt Resuscitation):

Discuss early (while patient has capacity to express wishes).
If capacity: Patient decides (can refuse CPR in advance).
If lacks capacity: Best interests decision (doctor + family). Consider: Likelihood of success (very low in advanced dementia), burdens vs benefits, patient's previously expressed wishes.
Document on ReSPECT form (Recommended Summary Plan for Emergency Care and Treatment) or equivalent.

Tube Feeding in Advanced Dementia:

Controversial. Evidence shows no benefit (does not prolong life, prevent aspiration pneumonia, or improve comfort in advanced dementia). [34]
NICE guideline: Do not routinely offer tube feeding in advanced dementia.
Some families/cultures request feeding tubes → Sensitive discussion. Explain lack of benefit, potential harms (aspiration, infection, restraint to prevent pulling out tube, loss of oral pleasure).
Best interests decision if patient lacks capacity.

Palliative Care:

Advanced AD = Terminal illness. Appropriate for palliative care approach (focus on comfort, dignity, quality of life).
Anticipatory medications: Prescribe PRN (as needed) medications for common end-of-life symptoms: Pain (morphine/oxycodone), Secretions (hyoscine), Agitation (midazolam/haloperidol), Nausea (cyclizine/levomepromazine).
Preferred Place of Care: Discuss early. Some prefer home, others care home/hospice. Rapid discharge arrangements if hospital death not wished.

Genetic Testing and Counselling

Predictive Testing (Asymptomatic at-risk individuals):

Autosomal Dominant AD (APP, PSEN1, PSEN2): If parent affected, 50% risk of inheriting mutation. Predictive testing available.
Ethical issues: No cure/prevention → Knowing mutation status causes psychological distress, impacts life decisions (family planning, career, insurance). Not recommended unless individual fully informed and counselled.
APOE genotyping: NOT recommended for predictive testing (APOE ε4 = risk factor, not deterministic). Many ε4 carriers never develop AD. Causes unwarranted anxiety. Professional societies (Alzheimer's Association, ACMG) advise against routine APOE testing in asymptomatic individuals.

Genetic Counselling Protocol:

Specialist genetics service.
Pre-test counselling (implications, limitations, psychological impact).
Psychiatric assessment (ensure stable mental health - risk of depression/suicide with positive result).
Post-test support.
Family implications (siblings, children also at risk).

Financial Abuse and Vulnerability

AD patients at high risk of financial exploitation:

Impaired judgment, memory, executive function → Vulnerable to scams, undue influence, theft (including by family members/carers).

Safeguarding:

LPA for Property and Financial Affairs (appoint trusted person early).
Bank alerts: Notify bank of diagnosis (some have vulnerable customer protocols).
Direct Debits: Set up for regular bills.
Monitor accounts: Family/attorney should review statements for unusual transactions.
Report abuse: If suspected financial abuse → Adult Safeguarding (Local Authority). Police if criminal.

19. References

Primary Sources (with DOIs)

Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628. doi:10.1016/S0140-6736(24)01296-0. PMID: 39096926.
Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. Lancet. 2021;397(10284):1577-1590. doi:10.1016/S0140-6736(20)32205-4. PMID: 33667416.
Long JM, Holtzman DM. Alzheimer disease: An update on pathobiology and treatment strategies. Cell. 2019;179(2):312-339. doi:10.1016/j.cell.2019.09.001. PMID: 31564456.
Knopman DS, Amieva H, Petersen RC, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7(1):33. doi:10.1038/s41572-021-00269-y. PMID: 33986301.
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018. PMID: 29653606.
Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-629. doi:10.1016/S1474-4422(14)70090-0. PMID: 24849862.
National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers (NG97). 2018. Available at: https://www.nice.org.uk/guidance/ng97
McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;3(3):CD003154. doi:10.1002/14651858.CD003154.pub6. PMID: 30891742.
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(9):9-21. doi:10.1056/NEJMoa2212948. PMID: 36449413.
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512-527. doi:10.1001/jama.2023.13239. PMID: 37459141.
Alzheimer's Disease International. World Alzheimer Report 2021: Journey through the diagnosis of dementia. 2021. Available at: https://www.alzint.org/resource/world-alzheimer-report-2021/
Podcasy JL, Epperson CN. Considering sex and gender in Alzheimer disease and other dementias. Dialogues Clin Neurosci. 2016;18(4):437-446. doi:10.31887/DCNS.2016.18.4/cepperson. PMID: 28179815.
Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63(2):168-174. doi:10.1001/archpsyc.63.2.168. PMID: 16461860.
Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106-118. doi:10.1038/nrneurol.2012.263. PMID: 23296339.
Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83(3):253-260. doi:10.1212/WNL.0000000000000596. PMID: 24928124.
Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6. PMID: 32738937.
Fann JR, Ribe AR, Pedersen HS, et al. Long-term risk of dementia among people with traumatic brain injury in Denmark: a population-based observational cohort study. Lancet Psychiatry. 2018;5(5):424-431. doi:10.1016/S2215-0366(18)30065-8. PMID: 29653722.
Cummings J, Zhou Y, Lee G, et al. Alzheimer's disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023;9(2):e12385. doi:10.1002/trc2.12385. PMID: 37397340.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259. doi:10.1007/BF00308809. PMID: 1759558.
Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215(4537):1237-1239. doi:10.1126/science.7058341. PMID: 7058341.
Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol. 2009;66(12):1447-1455. doi:10.1001/archneurol.2009.266. PMID: 20008648.
Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369. doi:10.1136/bmj.h369. PMID: 25731881.
Erickson KI, Hillman C, Stillman CM, et al. Physical Activity, Cognition, and Brain Outcomes: A Review of the 2018 Physical Activity Guidelines. Med Sci Sports Exerc. 2019;51(6):1242-1251. doi:10.1249/MSS.0000000000001936. PMID: 31095082.
Ju YS, Ooms SJ, Sutphen C, et al. Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels. Brain. 2017;140(8):2104-2111. doi:10.1093/brain/awx148. PMID: 28899014.
Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255-2263. doi:10.1016/S0140-6736(15)60461-5. PMID: 25771249.
Hansson O, Blennow K, Zetterberg H, Teunissen C. Blood biomarkers for Alzheimer's disease in clinical practice and trials. Nat Aging. 2023;3(5):506-519. doi:10.1038/s43587-023-00403-3. PMID: 37188874.
Shen Y, Niimi M, Hua Qian Z, et al. Artificial intelligence in Alzheimer's disease: clinical applications and challenges. Alzheimers Dement. 2024;20(1):679-699. doi:10.1002/alz.13448. PMID: 37773715.
Dumitrascu OM, Koronyo-Hamaoui M, Koronyo Y. Retinal imaging as a window to the brain in Alzheimer's disease. Neurosci Biobehav Rev. 2020;108:113-131. doi:10.1016/j.neubiorev.2019.11.006. PMID: 31730962.
Warren JD, Fletcher PD, Golden HL. The paradox of syndromic diversity in Alzheimer disease. Nat Rev Neurol. 2012;8(8):451-464. doi:10.1038/nrneurol.2012.135. PMID: 22801974.
World Health Organization. Global action plan on the public health response to dementia 2017-2025. Geneva: WHO; 2017. Available at: https://www.who.int/publications/i/item/global-action-plan-on-the-public-health-response-to-dementia-2017---2025
UK Government. Mental Capacity Act 2005. Available at: https://www.legislation.gov.uk/ukpga/2005/9/contents
Driver and Vehicle Licensing Agency. Assessing fitness to drive: a guide for medical professionals. 2022. Available at: https://www.gov.uk/guidance/assessing-fitness-to-drive-a-guide-for-medical-professionals
UK Government. Deprivation of Liberty Safeguards (DoLS). Available at: https://www.gov.uk/government/collections/dh-mental-capacity-act-2005-deprivation-of-liberty-safeguards
Sampson EL, Candy B, Jones L. Enteral tube feeding for older people with advanced dementia. Cochrane Database Syst Rev. 2009;(2):CD007209. doi:10.1002/14651858.CD007209.pub2. PMID: 19370678.

21. Examination Focus: MRCP/FRACP High-Yield Topics

High-Yield Exam Topics

1. Pathological Hallmarks

Question: "What are the two key pathological findings in Alzheimer's disease?"

Answer:

Extracellular Amyloid-beta (Aβ) Plaques: Composed of aggregated Aβ peptide (especially Aβ42). Neuritic plaques surrounded by dystrophic neurites, activated microglia, and reactive astrocytes.
Intracellular Neurofibrillary Tangles (NFTs): Composed of hyperphosphorylated tau protein forming paired helical filaments (PHFs). Spread follows Braak staging and correlates with cognitive decline.

2. First-Line Pharmacological Treatment

Question: "What is the first-line pharmacological treatment for mild-to-moderate Alzheimer's disease?"

Answer: Acetylcholinesterase Inhibitors (AChEIs):

Donepezil (most commonly used - once daily, 5-10mg)
Rivastigmine (patch preferred - 4.6-13.3mg/24h)
Galantamine (modified release - 8-24mg OD)

Mechanism: Inhibit acetylcholinesterase → Increase synaptic acetylcholine → Enhance cholinergic neurotransmission.

Efficacy: Modest symptomatic benefit (~6-12 month delay in decline). Do NOT halt disease progression.

3. Characteristic MRI Finding

Question: "What is the characteristic MRI finding in Alzheimer's disease?"

Answer: Bilateral Hippocampal (Medial Temporal Lobe) Atrophy.

Involves hippocampus, entorhinal cortex, parahippocampal gyrus.
Best seen on coronal T1 MRI.
Correlates with memory impairment severity.
Visual rating: Medial Temporal Lobe Atrophy (MTA) score (Scheltens scale).

4. Genetic Risk Factor

Question: "What is the major genetic risk factor for late-onset sporadic Alzheimer's disease?"

Answer: APOE ε4 allele (Apolipoprotein E epsilon-4).

Located on Chromosome 19.
Three alleles exist: ε2 (protective), ε3 (neutral - most common), ε4 (risk).
Heterozygotes (ε3/ε4): ~3x increased risk.
Homozygotes (ε4/ε4): ~12x increased risk. Earlier onset (may present in 60s).
NOT deterministic - Many ε4 carriers never develop AD.
Mechanism: ε4 variant less efficient at Aβ clearance, also affects tau, inflammation, vascular integrity.

5. Cholinergic Hypothesis

Question: "Explain the cholinergic hypothesis of Alzheimer's disease."

Answer:

Nucleus Basalis of Meynert (basal forebrain) provides cholinergic innervation to hippocampus and cortex.
In AD: Severe neuronal loss in NBM (~70-90%) → Profound acetylcholine deficiency in cortex and hippocampus.
Cholinergic system critical for memory, attention, executive function.
Deficit explains many cognitive symptoms of AD.
Therapeutic implication: Rationale for Acetylcholinesterase Inhibitor (AChEI) therapy to boost synaptic acetylcholine levels.

6. Braak Staging

Question: "Describe Braak staging in Alzheimer's disease."

Answer: Braak staging describes the anatomical progression of neurofibrillary tangles (tau pathology):

Stage I-II: Transentorhinal cortex → Clinically silent or very mild memory impairment.
Stage III-IV: Hippocampus and limbic regions → MCI or Mild AD. Memory deficits prominent.
Stage V-VI: Neocortical association areas (temporal, parietal, frontal) → Moderate-Severe AD. Global cognitive impairment.

Key Point: Tau pathology (NFTs) correlates better with cognitive decline than amyloid plaques.

7. Differential Diagnosis: AD vs FTD vs DLB

Question: "How do you differentiate Alzheimer's disease from Frontotemporal Dementia and Dementia with Lewy Bodies?"

Answer:

Feature	Alzheimer's Disease	Frontotemporal Dementia (FTD)	Dementia with Lewy Bodies (DLB)
First symptom	Memory loss (episodic)	Behaviour/Personality change or Language (aphasias)	Visual hallucinations, Parkinsonism, Fluctuating cognition
Age of onset	Usually > 65	Younger (50-60s)	Usually > 65
Memory early?	Yes - prominent	Relatively preserved early	Impaired but fluctuates
Motor features	None until late	Late (parkinsonism or MND)	Parkinsonism (rigidity, bradykinesia) early
Hallucinations	Uncommon	Rare	Recurrent, detailed visual hallucinations (core feature)
MRI pattern	Hippocampal + temporoparietal atrophy	Frontal and/or anterior temporal atrophy	Medial temporal lobes relatively preserved
Other clues	Gradual decline, elderly	Disinhibition, apathy, loss of empathy, language variants	REM sleep behaviour disorder, fluctuating cognition, neuroleptic sensitivity

8. CSF Biomarkers

Question: "What are the CSF biomarker changes in Alzheimer's disease?"

Answer:

Aβ42: Decreased (sequestered in plaques).
Total tau (t-tau): Increased (neuronal injury/death).
Phosphorylated tau (p-tau): Increased (tangle pathology).

AD Signature: Low Aβ42 + High tau + High p-tau.

9. Side Effects of AChEIs

Question: "What are the main side effects of acetylcholinesterase inhibitors?"

Answer:

GI (most common): Nausea, vomiting, diarrhoea, anorexia, weight loss (cholinergic effect on gut).
Cardiovascular: Bradycardia (enhanced vagal tone), syncope, heart block (caution in cardiac conduction disorders).
CNS: Insomnia, vivid dreams/nightmares (donepezil - give in morning if problem), dizziness, headache.
Urinary: Frequency, incontinence (increased bladder contractility).
Respiratory: Bronchospasm (caution in asthma/COPD).

Management: Start low, titrate slowly. Give with food (reduce GI SEs). Rivastigmine patch (less GI SEs). Check baseline ECG if cardiac history.

10. Memantine Mechanism

Question: "What is the mechanism of action of memantine?"

Answer: Non-competitive NMDA receptor antagonist.

Blocks excessive glutamate activity (glutamate excitotoxicity) which contributes to neuronal death in AD.
Allows physiological NMDA receptor activity (required for learning/memory) but prevents pathological overstimulation.
Used in moderate-to-severe AD (MMSE less than 20).
Can be combined with AChEI for additive benefit.
Well-tolerated (fewer side effects than AChEIs).

Viva Points

MMSE Limitations:

Ceiling effect: Misses mild cognitive impairment (highly educated patients may score normal despite deficits).
Floor effect: Severe dementia scores 0 - cannot differentiate severity.
Education/language bias: Not adjusted for education/culture.
ACE-III more sensitive: 100-point scale, assesses 5 domains, better for MCI detection.

Down Syndrome and Alzheimer's:

APP gene located on Chromosome 21 → Trisomy 21 (Down Syndrome) = Triple APP gene dosage → Lifelong overproduction of Aβ.
Nearly universal development of AD by age 40 in Down Syndrome.
Earliest onset dementia population.

Reversible Dementias - Always Screen For:

Vitamin B12 deficiency: Check B12, treat early (reversible if caught before irreversible damage).
Hypothyroidism: Check TFTs, treat with levothyroxine (reversible).
Depression (Pseudodementia): Low mood, poor effort on testing ("don't know" answers), reversible with antidepressants.
Normal Pressure Hydrocephalus (NPH): Triad (Gait disturbance + Urinary incontinence + Dementia), large ventricles on imaging, reversible with VP shunt.
Chronic subdural haematoma: History of head trauma (may be minor/remote), CT shows collection, reversible with drainage.

Driving and Dementia:

Must notify DVLA (legal requirement in UK).
DVLA decides fitness to drive, not the doctor (doctor advises, DVLA assesses).
DVLA may require: Cognitive assessment, on-road driving test.
Many will need to stop driving for safety (impaired judgment, visuospatial deficits, reaction time).

Anti-Amyloid Therapies (New):

Lecanemab, Donanemab: Monoclonal antibodies targeting Aβ.
FDA approved (2023-2024). NICE reviewing (cost-effectiveness concerns).
Modest clinical benefit (~27% slower decline) in early AD (MCI due to AD, mild AD).
Require: Confirmed amyloid pathology (PET/CSF), IV infusions (Q2W or Q4W), MRI monitoring (ARIA risk).
ARIA (Amyloid-Related Imaging Abnormalities): Oedema (ARIA-E), microhaemorrhages (ARIA-H). Usually asymptomatic. Higher risk in APOE ε4 homozygotes.

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines for patient management.

Clinical board

Urgent signals

Exam focus

Linked comparisons

Editorial and exam context

Topic family

Alzheimer's Disease

1. Clinical Overview

Summary

Clinical Pearls

2. Epidemiology

Global Burden

Demographics

Age-Specific Prevalence

Classification by Age of Onset

Risk Factors

Non-Modifiable Risk Factors

Modifiable Risk Factors (Vascular and Lifestyle)

Protective Factors

3. Pathophysiology

Macroscopic Pathology

Microscopic Pathology: Hallmark Features

1. Amyloid-Beta (Aβ) Plaques

2. Neurofibrillary Tangles (NFTs)

3. Braak Staging (Neuropathological Progression of Tau)

4. Neuronal Loss and Synaptic Dysfunction

5. Cholinergic Deficit

6. Neuroinflammation

Molecular Pathophysiology: The Amyloid Cascade Hypothesis

Genetics

Familial Alzheimer's Disease (Autosomal Dominant - Early Onset)

Sporadic Alzheimer's Disease (Late Onset)

4. Differential Diagnosis

5. Clinical Presentation

Natural History and Stages

Preclinical AD (Asymptomatic)

Mild Cognitive Impairment (MCI) due to AD

Mild AD (Early Dementia)

Moderate AD (Middle Stage Dementia)

Severe AD (Late Stage Dementia)

Symptom Domains: Detailed Features

A. Memory (Hallmark Feature)

B. Language

C. Visuospatial Function

D. Executive Function

E. Behavioural and Psychological Symptoms of Dementia (BPSD)

6. Investigations

Diagnostic Approach: NIA-AA Criteria for AD Dementia

Cognitive Assessment Tools

Blood Tests: Exclude Reversible Causes

Neuroimaging

Structural Imaging (MRI Brain - Preferred)

Functional and Molecular Imaging (Specialist Use)

Cerebrospinal Fluid (CSF) Biomarkers (Specialist - Not Routine)

Other Investigations

7. Management

Principles of Management

Management Algorithm

Pharmacological Management: Detailed

Acetylcholinesterase Inhibitors (AChEIs)

Memantine

When to Stop Medications

Emerging Disease-Modifying Therapies

Anti-Amyloid Monoclonal Antibodies [9,10]

Non-Pharmacological Management

Carer Support

Treatment Monitoring and Discontinuation

When to Stop AChEIs/Memantine

Assessing Treatment Response

8. Complications

9. Prognosis and Outcomes

Survival

Factors Affecting Prognosis

Progression Rate

Cause of Death

Quality of Life

Effect of Treatment on Prognosis

10. Evidence and Guidelines

Key Guidelines

Landmark Trials and Evidence